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The number of neutrophils in the blood is tightly regulated to ensure adequate 
protection against microbial pathogens while minimizing damage to host tissue.  
Neutrophil homeostasis in the blood is achieved through a balance of neutrophil 
production, release from the bone marrow, and clearance from the circulation.  
Accumulating evidence suggests that chemokine signaling in the bone marrow may play 
a key role in maintaining neutrophil homeostasis.  Based on this evidence, we developed 
a “tug-of-war” model in which opposing chemokine gradients, specifically release-
inducing CXCR2 signals and retention-promoting CXCR4 signals, act antagonistically to 
regulate neutrophil release from the bone marrow.  We generated mice with neutrophils 
genetically deficient for the receptors CXCR2 (CXCR2
-/-
), CXCR4 (CXCR4
-/-
), or both 
(double knock-out or DKO) in order to define the mechanisms by which chemokine 
signals regulate neutrophil homeostasis. 
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We show that CXCR4 negatively regulates neutrophil release from the bone 
marrow in a cell autonomous fashion.  However, CXCR4 is dispensable for neutrophil 
clearance from the circulation.  Neutrophil mobilization responses to granulocyte colony 
stimulating factor (G-CSF), CXCL2, or Listeria monocytogenes infection are absent or 
impaired in CXCR4
-/- 
neutrophils, suggesting that disruption of CXCR4 signaling may be 
a common step mediating neutrophil release. 
CXCR2
-/-
 neutrophils exhibit abnormal retention in the bone marrow and a 
peripheral neutropenia, which replicates the phenotype of the human disease 
myelokathexis and indicates that CXCR2 positively regulates neutrophil release from the 
bone marrow.  CXCR2
-/- 
neutrophils do not mobilize in response to an inhibitor of 
CXCR4 and have an impaired response to G-CSF, suggesting that neutrophil release 
requires the coordinated regulation of CXCR2 and CXCR4 signals.  However, DKO 
neutrophils exhibit a shift from the bone marrow to the blood that is similar to CXCR4
-/-
 
cells, indicating that CXCR4 is dominant to CXCR2 and that there are likely to be 
CXCR2-independent mechanisms for directing neutrophil release. 
Finally, we show that there is differential production of CXCR2 and CXCR4 
ligands by bone marrow osteoblasts and endothelial cells that can be regulated by G-CSF. 
Taken together, our data suggest that coordinated osteoblast and endothelial production 
of CXCR2 and CXCR4 ligands is a common mechanism controlling neutrophil release 
from the bone marrow.   
iv 
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Introduction 
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1.1 Overview and goals 
The overall goal of this project was to characterize mechanisms that regulate circulating 
neutrophil counts and thus the ability of neutrophils to traffic to sites of inflammation and 
perform their various anti-bacterial functions.  Particular emphasis was placed on factors 
governing neutrophil mobilization (the release of neutrophils from the bone marrow, the 
site of neutrophil production and maturation, into the blood) under either basal or 
inflammatory conditions. 
The number of circulating neutrophils is tightly regulated in order to effectively 
protect against microbial pathogens while minimizing damage to host tissue. Homeostatic 
control of neutrophils in the blood is achieved through a balance of neutrophil 
production, release from the bone marrow, and clearance from the circulation. 
Accumulating evidence suggests that signaling by the chemokine CXCL12 (SDF-1), 
through its major receptor CXCR4, plays a key role in controlling neutrophil homeostasis 
by acting as a bone marrow retention signal.  Alteration of CXCR4 signaling by genetic 
mutations, pharmacologic agents, or an inflammatory stimulus changes the number of 
circulating neutrophils.  The role of CXCR4 in regulating neutrophil homeostasis under 
basal and stress conditions is investigated using a genetically defined model in Chapter 2 
of this thesis.  However, recent genetic data in humans and work detailed in Chapter 3 of 
this thesis have implicated additional chemokines and chemokine receptors in the 
regulation of neutrophil homeostasis.  In Chapter 3, the role of CXCR2 chemokines in 
neutrophil trafficking from the bone marrow is investigated using neutrophils genetically 
deficient for CXCR2. 
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The work in this thesis supports the hypothesis that the degree of neutrophil 
mobilization is regulated by the balance of retention-promoting CXCL12/CXCR4 signals 
and release-inducing CXCR2 signals.  We show that this may be a shared mechanism of 
action among diverse types of mobilizing agents.  Our experiments delineate the cell-
intrinsic and cell-extrinsic effects of CXCR2 and CXCR4 in the regulation of neutrophil 
trafficking.  We investigate the role of these chemokines in neutrophil migration from the 
circulation into peripheral tissues and subsequent clearance.  Finally, we begin to 
characterize the cellular sources of chemokines within the bone marrow.  This thesis 
provides a more detailed picture of chemokine functions in neutrophil biology.  
Dysregulated neutrophil counts are implicated in numerous disease states, from bacterial 
infections in the setting of inherited or iatrogenic neutropenia to inflammatory diseases 
like atherosclerosis or arthritis that are associated with excessive neutrophils.  Therefore, 
this work also increases our understanding of the pathophysiology and suggests potential 
treatments of some of these diseases. 
 
1.2  Homeostatic control of circulating neutrophil counts 
Neutrophils are leukocytes comprising a key component of the innate immune system, 
and they play a primary role in establishing an inflammatory response.  Their main 
functions are to phagocytose and kill bacteria while also producing inflammatory 
mediators that allow resolution of the infection and establishment of long-lasting, 
adaptive immunity via other cells of the immune system.  Patients with congenital or 
acquired neutropenia are extremely susceptible to severe, life-threatening bacterial 
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infections, although the advent of antibiotic and cytokine therapy has lessened this risk 
(1, 2).  Conversely, excessive neutrophil accumulation at sites of inflammation can 
damage host tissue and contributes to disease pathogenesis in a number of acute and 
chronic human diseases.  For example, neutrophils are thought to be key mediators of 
disease in acute respiratory distress syndrome and rheumatoid arthritis.  In murine models 
of atherosclerosis (3) and autoimmune encephalitis(4), neutrophils have been shown to 
play a causative role in the disease process.  Thus, circulating neutrophil counts must be 
tightly controlled in order to minimize the risk from both infectious and inflammatory 
disease. 
 
1.2.1 Normal baseline neutrophil counts and clinical relevance 
Neutrophil counts exhibit little variation within an individual during times of health, but 
there is considerable variation between individuals (Figure 1-1A) (5).  This variation is 
likely to have a genetic basis, as it is dependent on ethnic background.  In a large 
population study, Caucasians had a mean neutrophil count of 4.4 x 10
9
/L, while that of 
African Americans was 3.65 x 10
9
/L.  Mice also exhibit variation that is dependent on 
genetic background (Figure 1-1B).  Of note, whole genome association studies in model 
organisms have revealed chromosomal regions associated with neutrophil counts, 
including a region containing the CXCR2 chemokine CXCL8, but specific 
polymorphisms and their functional consequences were not identified (6). 
 In humans, total white blood cell counts (WBC) at baseline are mostly determined 
by their main component, neutrophils.  Underscoring the importance of the regulation of 
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neutrophil counts, variation in WBCs has been associated with increased mortality.  In 
one study, as WBC and neutrophil, but not lymphocyte, counts moved away from a 
central number (approximately the mean of the population), they were associated with 
increased all-cause mortality (Figure 1-1C).   Excessively low counts would predispose to 
infection with common pathogens, while increased counts are independent risk factors for 
cardiovascular (7) and cancer mortality (8).  Notably, mice have much lower circulating 
neutrophil counts than humans and also do not naturally develop cardiovascular disease 
(Figure 1-1B,C).  These observations are concordant with accumulating research 
demonstrating that inflammation plays a key role in both cardiovascular disease and 
cancer.  It is unclear whether alterations in neutrophil homeostasis play a causative role in 
these diseases or simply reflect underlying inflammatory processes. 
 
1.2.2 Kinetics of neutrophil production and clearance 
Given their key role in both infectious and inflammatory diseases, precise regulation of 
circulating neutrophil levels is therefore required.   In the average man, over 100 billion 
mature neutrophils must enter the circulation from the bone marrow each day in order to 
maintain homeostasis; the blood neutrophil pool is turned over 2.3 times each day with a 
half-time of disappearance from the blood of only 6.8 hours (2, 9, 10).  The bone marrow 
postmitotic transit time is 4 days in mice (11) and 7 days in humans (12), demonstrating 
that the vast majority of post-mitotic neutrophil lineage cells are stored in the bone 
marrow.  In comparison to a turnover rate on the order of months for erythrocytes, the 
rapid kinetics of neutrophils show that complex yet precise regulatory mechanisms are 
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likely to control neutrophils.  At another level of regulatory complexity, circulating 
neutrophil numbers are rapidly increased in response to infectious stimuli or other stress 
conditions in a process termed “emergency granulopoiesis”. 
Neutrophil homeostasis (5, 13) is determined by regulation of three main 
processes:  neutrophil production in the bone marrow, neutrophil release from the bone 
marrow into the circulation, and neutrophil clearance from the blood by adhesion, 
transmigration, apoptosis, and phagocytosis in the tissues.  As detailed below, much 
research has been directed toward describing neutrophil responses in health and disease 
and determining the processes, cell types, molecules, and signaling pathways that 
regulate these responses.  However, many questions remain incompletely answered. 
 
1.3 Neutrophil production 
The production and maturation of neutrophils in the bone marrow, or granulopoiesis, is 
the process by which a small number of pluripotent, self-renewing hematopoietic stem 
cells give rise to mature neutrophils through a number of cell division and differentiation 
steps.  Stem cells give rise to increasingly differentiated progenitor cells (14).  
Granulocyte progenitors undergo characteristic differentiation through myeloblast, 
promyelocyte, myelocyte, and metamyelocyte forms before becoming mature 
polymorphonuclear granulocytes (PMNs) that can be described as either band or the more 
mature segmented form depending on the morphology of the nucleus.  It is now known 
that the development of different lineages of hematopoietic cells (lymphocyte, erythroid, 
megakaryocyte, myeloid and subsets thereof) is governed by specific cytokines providing 
7 
extracellular signals to less differentiated cells and the subsequent activation or 
repression of transcriptional programs by characteristic transcription factors.  To 
characterize these transcriptional programs, Theilgard-Monch et al undertook a 
comprehensive microarray analysis of gene expression in cells at various stages of 
neutrophilic differentiation (15).  They showed that neutrophil maturation was associated 
with a downregulation of proliferative networks, engagement of various anti-apoptotic 
pathways, expression of host defense effector molecules, and, only upon terminal 
differentiation, the acquisition of receptors required to activate neutrophil host defense 
functions. 
 
1.3.1 Transcriptional control 
Several recent reviews have covered the transcription factors that regulate neutrophil 
development and differentiation (16-18).  Briefly, the main transcription factors 
governing myeloid development, in order from earliest to latest, are PU.1, CCAAT 
enhancer binding proteins alpha and epsilon (C/EBPα and C/EBPε), and GFI-1.  Genetic 
deletion of any of these factors results in blocks at specific stages of differentiation and 
absence of the appropriate progeny cells.  PU.1 is required for the formation of common 
myeloid progenitors (CMP) and the production of B lymphocytes, monocytes, 
neutrophils, and eosinophils.  C/EBPα is a later transcription factor that is necessary to 
form granulocyte/monocyte progenitors (GMP) and produce mature cells of those 
lineages.  C/EBPε and GFI-1 are necessary and non-redundant for the final stages of 
neutrophil maturation, as mice lacking either of these proteins have a differentiation 
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block at the promyelocyte stage and absent or abnormal neutrophil production.  The 
block is associated with a lack of the secondary and tertiary granule proteins that are 
characteristic of mature granulocytes.  Subsequent studies utilizing conditional 
expression or more precise assays have shown all of these transcription factors to have 
additional, overlapping functions in many other hematopoietic processes, particularly in 
regulating hematopoietic stem cell function and providing a “differentiation block” 
though to be necessary in the pathogenesis of leukemia.  Specifically,  PU.1 (19) and 
C/EBPα (20) mutations or suppression of these genes by the leukemogenic fusion protein 
PML-RARα (21) are associated with acute myeloid leukemia (AML).  A small subset of 
severe congenital neutropenia cases has been associated with mutations in the 
transcription factors GFI-1, HAX-1, and LEF-1 (22, 23).   
 
1.3.2 G-CSF:  The principle cytokine controlling granulopoiesis 
In addition to intrinsic transcription factors governing the production of neutrophils in the 
bone marrow, extrinsic signals are also required.  For hematopoietic cells in general, one 
of the key mechanisms of extrinsic regulation is by cytokines and growth factors, and the 
essential cytokine controlling neutrophil production is the granulocyte colony stimulating 
factor, or G-CSF (reviewed in Basu et al (24) and Panopoulos and Watowich (25)).  G-
CSF was one of the first cytokines to be isolated, and it has since been shown to have 
numerous roles in both basal and stress granulopoiesis.  G-CSF was purified from human 
placental (26) or murine lung (27) conditioned medium on the basis of its ability to 
stimulate the growth of granulocyte colonies from bone marrow cells.  The murine (28) 
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and human (29, 30) cDNA for G-CSF was subsequently cloned based on protein 
sequence and species homology, and this enabled expression of recombinant protein and 
other tools to further investigate the function of G-CSF.  G-CSF expression is induced in 
numerous different cell types upon stimulus with appropriate immunogenic factors such 
as LPS, TNFα, INFγ, or IL-1β, which would be expected given the key role of G-CSF in 
stimulating neutrophil production to help mount an appropriate immune response.  
Transcription is initiated by the binding of NF-κB p60 and NF-IL6 at their binding sites 
in the promoter region (31).  G-CSF expressing cells include hematopoietic cells such as 
monocytes, granulocytes, T lymphocytes, and macrophages as well as stromal cells, 
fibroblasts, endothelial cells, and mesothelial cells (32).  Most cells express very low 
levels of basal G-CSF expression, although many tumor cells have constituitive 
expression. 
Consistent with this, at baseline there are low but detectable levels of serum G-
CSF that increase dramatically in response to infection along with an increase in the 
circulating neutrophil count (33).  G-CSF treatment causes neutrophilia (34-37) resulting 
from increased proliferation of myeloid precursors and decreased transit time through the 
post-mitotic compartment in the bone marrow (38-40).  As a result, G-CSF is used 
clinically to treat neutropenia and prevent infections.  In vitro, G-CSF treatment 
stimulates the proliferation of myeloid progenitors (41). 
At the molecular level, the effects of G-CSF are mediated by signaling through 
the G-CSF receptor (G-CSFR).    The G-CSFR is a member of the hematopoietic 
cytokine receptor family and consists of single extracellular, transmembrane, and 
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cytoplasmic domains.  The N-terminal portion of the cytoplasmic domain binds and 
activates JAK kinases, which phosphorylate tyrosines on the C-terminal portion of the 
cytoplasmic tail and activate STAT proteins.  Other signals are transmitted through the 
RAS-ERK1/2 pathway and cytoplasmic kinases such as LYN and SYK.  The main target 
cells of G-CSF, hematopoietic stem cells, myeloid progenitor cells, and granulocytes and 
their precursors, express the G-CSFR, and its expression is upregulated as the cells 
mature (42).  However, other hematopoietic and stromal cell types, including endothelial 
cells (43), also express the GCSFR . 
Genetic evidence that G-CSF signals are required for normal neutrophil 
production was provided by the identification of rare, dominant negative mutations in the 
G-CSFR in humans with severe congenital neutropenia (44-46).  Conversely, a pedigree 
with chronic neutrophilia and constitutively active G-CSFR mutations has also been 
recently reported (47).  A definitive role for G-CSF in controlling neutrophil production 
was shown by studies in transgenic mice.  Both G-CSF-deficient (CSF3
-/-
)
 
(48) and G-
CSFR-deficient (CSF3R
-/-
) (49) mice exhibit a profound but not absolute neutropenia 
along with reduced numbers of myeloid cells in the bone marrow.  The evidence suggests 
that G-CSF controls granulopoiesis through a number of different mechanisms.  Early in 
myeloid development, it is necessary for commitment of primitive progenitors to the 
myeloid pathway (50).  In CSF3
-/-
 or CSF3R
-/-
 mice, there is decreased proliferation of 
myeloid progenitors and decreased survival as evidenced by increased susceptibility to 
apoptosis (11).  However, expression of a GCSFR engineered to contain a cytoplasmic 
tail that was either truncated (D715) or replaced with the cytoplasmic tail of the 
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erythropoietin receptor (GEPOR) showed that the distal portion of the GCSFR 
cytoplasmic tail was dispensable for G-CSF induced granulocytic differentiation, but 
required for other functions of G-CSF as discussed below (51, 52).  Conversely, STAT3 
activation mediated by JAK kinase attachment at the proximal cytoplasmic portion of the 
G-CSFR upon ligand binding is required for normal myeloid cell proliferation and 
neutrophil development (53).  G-CSF signals are necessary for appropriate release of 
neutrophils from the bone marrow into the blood under both basal and stress conditions 
(discussed below).  Lastly, G-CSF is important for neutrophils to function appropriately 
in arriving at the site of infection and displaying bacteriocidal activity.  Neutrophils 
lacking a complete G-CSFR had impaired chemotaxis and adhesion molecule 
upregulation (52, 54), while neutrophils from CSF3
-/-
 mice had morphological defects, 
impaired phagocytosis, and defective nitric oxide production (55).  Additionally, G-CSF 
treatment of wild-type neutrophils activates them and enhances phagocytosis, superoxide 
anion generation, and bacterial killing (56). 
 
1.3.3 Additional mechanisms 
 Several other factors that regulate neutrophil production deserve mention but will 
not be covered in detail.  Effective granulopoiesis requires proliferative signals from 
cytokines, but these signals must be dampened by negative regulatory molecules within 
the cell to prevent excessive production of neutrophils.  It is important to note that 
numerous other cytokines besides G-CSF have been shown to have a role in 
granulopoiesis, including GM-CSF, M-CSF, IL-3, IL-6, IL-17, and IL-23 (57-62).  
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Indeed, mice lacking G-CSF, GM-CSF, and M-CSF could still produce neutrophils (63), 
showing that many compensatory pathways are likely to exist that are non-essential in the 
presence of G-CSF (e.g. GM-CSF, IL-3, IL-6).  Studies of mice with genetic alterations 
in the signaling molecules STAT3 or SOCS3 showed that they were negative regulators 
of G-CSF-induced neutrophil production that act by dampening G-CSF signaling (64, 
65).  Finally, given their rapid production and subsequent destruction and toxic granule 
components, neutrophils must maintain tight control over apoptosis.  The pro-apoptotic 
molecule BIM and anti-apoptotic MCL-1 seem to be the key regulators of this process in 
myeloid lineage cells including neutrophils (66, 67). 
 
1.4 Regulation of neutrophil release 
After neutrophil production in the bone marrow, a second regulatory checkpoint for 
neutrophil homeostasis is the control of neutrophil egress from the bone marrow into the 
circulation. 
 
1.4.1 Bone marrow architecture and composition 
Like all other blood cells, neutrophils are produced in the bone marrow hematopoietic 
compartment, an extravascular space characterized by dense cords of hematopoietic 
tissue.  The bone marrow extracellular matrix (ECM) has a typical composition of 
various types of collagen, proteoglycans, and glycoproteins (68).  In order to enter the 
circulation, neutrophils must transmigrate across a vascular barrier into venous sinuses 
dispersed throughout the marrow cavity (69).  As demonstrated by ultrastructural studies, 
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the vascular wall of the venous sinus is physically made up of three layers:  endothelial 
cells, a basement membrane, and adventitial cells (Figure 1-2A-C) (70, 71).  In some 
places, the membranes of the endothelial cells are fused, forming openings known as 
diaphragmed fenestra through which cells can cross into the circulation (71, 72).  Thus, 
migration across the endothelium occurs via a transcellular route, although passage 
through the adventitial cell layer occurs via a paracellular route.  This process, also 
known as neutrophil mobilization, must be highly regulated since only mature neutrophils 
of band or segmented nuclear morphology are released under basal conditions, despite 
the enormous amount of neutrophils produced in the marrow space daily.  In addition to 
the endothelium-associated cells mentioned above, other stromal cells in the bone 
marrow include adipocytes, macrophages and various osteoblast lineage cells (68).  
Together, the ECM and various stromal cells are thought to form niches for 
hematopoietic cells that regulate their development, function, and survival, but there is 
limited knowledge about the specific molecules that might mediate these interactions. 
Modulation of adhesive interactions with the ECM and stromal cells, chemotaxis 
toward the endothelium, and transmigration across the vascular barrier must logically 
occur for neutrophils to exit the bone marrow.  The molecules known to be involved in 
these processes are discussed below, and a major contribution of this thesis is to further 
define the regulators of neutrophil egress from the bone marrow.  Additional avenues of 
investigation for defining additional molecules that play a role will be discussed in 
Chapter 4. 
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1.4.2 Neutrophil mobilization by G-CSF 
Second, the regulatory mechanism is flexible enough to allow a dramatic and rapid 
increase in the circulating neutrophil count in response to infection or other bodily stress 
in a process termed “emergency granulopoiesis”.  For example, under basal conditions, 
only 1-2% of the total body neutrophils are present in the circulation, with a large portion 
of the remainder held as a “ready reserve” in order to respond to infection or other acute 
demand (73).  However, after treatment with G-CSF, the release of neutrophils into the 
blood increases so that the blood contains ~10% of the total neutrophils.  Further 
experiments showed that the release was dependent upon signals generated by the 
membrane proximal portion of the G-CSFR acting in a non-cell intrinsic manner (74).  G-
CSF treatment also acutely increases the circulating neutrophil count (36, 37), in sum 
showing that G-CSF is a potent regulator of neutrophil release in addition to stimulating 
neutrophil production. 
 
1.4.3 Emergency granulopoiesis and mobilizing agents 
Many diverse compounds can induce neutrophil release (or production) in addition to G-
CSF.  It is important to note that neutrophil production and release are closely interrelated 
processes that can be difficult to separate.  In general, rapid responses are more 
attributable to release since additional neutrophils have not been produced yet.  
Furthermore, neutrophil production and release may be regulated by distinct mechanisms 
under basal versus stress conditions.   Emergency granulopoiesis may utilize multiple 
pathways with additive or supplementary effects upon the basal regulatory machinery, 
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while regulation under homeostatic conditions may be relatively less complex.  However, 
even without clinical infection, animals are constantly being exposed to bacteria, 
indicating that basal versus stress processes likely are a continuum rather than two 
distinct entities. 
A stress granulopoiesis response is characterized by release of neutrophils from 
the marrow in its early phase and supplemented by increased production of neutrophils 
via increased myeloid progenitor commitment, increased cell cycling, and increased 
immature myeloid cells in its later phase.  Consistent with their biological function, a 
neutrophil response can be elicited by bacterial infection.  For example, granulopoiesis is 
enhanced by intratracheal Escherichia coli infection (75).  CSF3
-/-
 mice fail to generate a 
neutrophilia and have impaired clearance of intravenous Listeria monocytogenes 
compared to wild type controls.  However, with intraperitoneal infection CSF3
-/- 
mice had 
a normal neutrophilia but were still susceptible to infection (76).  When infected with 
Candida albicans, neutrophils were mobilized in a G-CSF, GM-CSF, and IL-6 
independent manner (77).  Neutrophil mobilization was impaired in CSF3R
-/-
 mice 
responding to pulmonary Pseudomonas aeruginosa infection (78).  G-CSF signals seem 
to be necessary for emergency granulopoiesis in some infections, but there are redundant 
signals in other cases.  In all cases, an increase in circulating neutrophils could be elicited 
by administration of an infectious agent, and this increase was needed for effective 
bacterial clearance. 
 Many other substances can also cause neutrophil release; they are generally in the 
category of inflammatory mediators produced in response to infection, but there are 
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examples outside of this paradigm as well.  Classes of molecules include cytokines, 
chemokines, leukotrienes, bacterial products, and complement factors.  Specific examples 
of agents that stimulate emergency granulopoiesis or neutrophil release include the 
hematopoietic cytokines TNFα (79), TNFβ, G-CSF (36), GM-CSF (80), IL-1 (79), IL-3 
(81), and IL-6 (82), the chemokine CXCL8 (IL-8) (83), leukotriene B4 (84), bacterial 
endotoxin (LPS) (85), C5a (84), platelet activating factor (PAF) (84), the peptide N-
formyl-met-leu-phe (fMLF) (84), prostaglandin analogues, epinephrine, corticosteroids, 
and even lithium (86).  Many of these agents have been documented to increase during 
infection, and IL-6 (62) and GM-CSF (76) are required for appropriate resolution of 
infection in experiments utilizing gene-deficient mice.  The kinetics of these agents are 
variable, with peak responses occurring anywhere from one to twelve hours after 
treatment.  This suggests that multiple pathways are involved that have several steps.  
Indeed, one could envision that agents with delayed responses must induce secondary 
mediators, while agents with more rapid responses may act more directly upon 
neutrophils and be downstream steps in the pathway.  Some of these agents, such as 
CXCL8 or C5a, also activate neutrophils and direct their chemotaxis.  Mice genetically 
deficient for GM-CSF (87), IL-3 (88), or IL-6 (62) display normal hematopoiesis, 
indicating that these cytokines are not required for basal granulopoiesis despite their 
potential involvement in stress granulopoiesis.  Conversely, mice deficient for both the 
G-CSFR and IL-6 display neutropenia of greater severity than that of the CSF3R
-/-
 
mouse, suggesting that IL-6 does play a role in basal granulopoiesis (89).  Lastly, at least 
one second messenger has been shown to be important in mediating neutrophil release.  
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Mice deficient in STAT3, one of the main intracellular tranducers of G-CSF signals, are 
unable to acutely mobilize neutrophils in response to G-CSF treatment, but have 
increased basal levels of peripheral neutrophils (90).  This suggests an inadequate reserve 
of immature neutrophils in STAT3
-/-
 mice and the possibility of distinct pathways 
operating in basal versus acute neutrophil release.  In sum, many pathways can lead to 
neutrophilia.  However, the steps that lead from elevation of an inflammatory mediator to 
neutrophil release into the circulation are relatively unknown.  The work presented in this 
thesis supports the idea that chemokine signaling in the bone marrow is a common final 
step mediating neutrophil trafficking from the bone marrow under both basal and stress 
conditions.  The current knowledge of mechanisms governing neutrophil release from the 
bone marrow is summarized below. 
 
1.4.4 Adhesion molecules 
It is well known that adhesion molecules regulate the egress of leukocytes from the blood 
into the tissues to arrive at sites of inflammation or immune surveillance (91-93).  The 
major adhesion molecules regulating neutrophils are integrins and selectins.  Of note, a 
considerable portion of the intravascular pool of neutrophils are marginated at the vessel 
walls and thus not reflected in blood neutrophil counts; the marginated pool can 
constitute up to one-half of the total intravascular pool (9).  This pool can vary depending 
on neutrophil activation state and be “mobilized” by certain stimuli. 
Humans with leukocyte adhesion deficiency (LAD) exhibit neutrophilia and 
increased susceptibility to infection secondary to impaired neutrophil migration into 
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tissues caused by genetic deficiency of β2-integrins (LAD I), selectin signaling (LAD II), 
or downstream signaling molecules (LAD III) (5).  A number of adhesion molecule-
deficient mice have been generated, and they all exhibit increased circulating neutrophils, 
reproducing the phenotype of LAD syndromes (5).  These observations are consistent 
with the requirement for the various classes of molecules at various steps of the leukocyte 
adhesion cascade that regulates exit from the circulation.  The neutrophilia in LAD mice 
is invariably associated with elevated serum levels of IL-17, the key observation that 
allowed elucidation of the homeostatic feedback loop described below (94).  In β2-
integrin-deficient (ITGB2
-/-
) mice, neutrophil counts normalize with the addition of wild-
type hematopoietic cells in bone marrow chimeras (94, 95).  These studies together 
showed that LAD neutrophilia is not caused by the passive accumulation of neutrophils 
in the circulation or altered proliferation.  Of note, neutrophil apoptosis is decreased in 
ITGB2
-/-
 mice but not in ITGB2
-/-
 neutrophils from bone marrow chimeras that also 
contain wild-type cells (96). 
Recent investigations have focused on whether adhesion molecules could play a 
role in the movement of neutrophils from the extravascular space of the bone marrow into 
the circulation.  This idea is supported by the fact that adhesion molecules are important 
in regulating the survival and release of other cell populations in the bone marrow, 
particularly hematopoietic stem cells (97).  Mice carrying genetic deletions of these 
molecules provide tools to test this hypothesis, but observations must be interpreted with 
caution because these mice often have elevated white cell counts secondary to excessive 
granulopoietic cytokine production (described below).  Administration of blocking 
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antibodies for CD18 (β2-integrins) or L-selectin had no effect on the neutrophilia induced 
by C5a, TNFα, or fMLF (98).  Using an in situ perfusion model to precisely measure 
neutrophils mobilized from one femur in response to the chemokine CXCL2 (MIP-2), 
Burdon et al assessed the effect of blocking or modulating the adhesion molecules CD18, 
VLA-4 (α4β1 integrin), or L-selectin on mobilization.  Their results suggested that CD18 
retains neutrophils in the bone marrow, while VLA-4 plays an opposing role by 
augmenting neutrophil release and L-selectin is dispensible (99).    Consistent with this, 
irradiated mice reconstituted with a mixture of wild type and ITGB2
-/-
 cells had increased 
percentages of neutrophils in ITGB2
-/-
 circulating leukocytes (95).  However, another 
group reports that there was no evidence for altered neutrophil mobilization in selectin-
deficient or ITGB2
-/-
 
-
 neutrophils in mixed bone marrow chimeras (5).  No abnormalities 
in neutrophil release have been described in α4-integrin (100) or L-selectin deficient mice 
(101, 102).  Finally, in contrast to the results obtained after mobilization by CXCL2, 
Petty et al showed that blockade of VLA-4 or its receptor VCAM-1 resulted in increased 
neutrophil mobilization that was augmented by CXCR4 inhibition (103).  They also 
suggested that CXCR4 stimulation increased VLA-4/VCAM-1 adhesion in a pertussis 
toxin-dependent manner.  
Thus, the data on the role of adhesion molecules in neutrophil mobilization are 
contradictory and likely to be highly dependent on the details of the experimental system 
employed.  Clearly, further experiments must be performed to fully characterize the role 
of adhesion molecules in the regulation of neutrophil release from the bone marrow.  
Some adhesion molecules may play redundant roles.  The cell-intrinsic role of these 
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molecules has not been clearly defined in genetically deficient mice.  CXCL2 is an 
inflammatory chemokine important for neutrophil mobilization from the marrow and 
homing to inflamed tissues, but in general the role of adhesion molecules in stress 
granulopoiesis has not been characterized. 
 
1.4.5 Neutrophil homeostatic feedback loops 
Homeostatic negative feedback loops controlling circulating neutrophil numbers have 
been suggested in the literature (95, 104), but no data to support them had been presented.  
Recent work (94, 105, 106) provides evidence that IL-17 production by specialized T-
cells stimulates G-CSF production, which in turn positively regulates granulopoiesis 
(Figure 1-3).  IL-17 production is positively regulated by IL-23 produced by 
macrophages and dendritic cells in the gut.  These cells decrease their production of IL-
23 upon phagocytosing apoptotic neutrophils, thus providing a way to match neutrophil 
production with neutrophil clearance.  Consistent with such a feedback loop, mice that 
overexpress IL-17 or IL-23 are neutrophilic (60, 107), while the mice genetically 
deficient for these cytokines or their receptors are neutropenic and/or have impaired 
neutrophil responses to stress or infection (59, 106, 108).  Bone marrow transplant 
experiments subsequently confirmed that hematopoietic cells are the source of IL-23 
(107), while the cells that respond to IL-17 and produce G-CSF in vivo are non-
hematopoietic stromal cells (108).  An earlier report had demonstrated that IL-17 could 
stimulate the production of G-CSF, IL-6, CXCL8, and prostaglandin E2 (PGE2) in 
epithelial, endothelial, and fibroblastic cells in vitro (109).  It is not yet clear how this 
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negative feedback loop becomes a positive feedback loop during infectious conditions, as 
the number of neutrophils in the tissues is increased, yet G-CSF production and 
subsequent granulocyte proliferation and mobilization into the blood remain elevated for 
the duration of the infectious episode.  However, IL-17 signaling is required for an 
effective innate immune response in murine models of Toxoplasma gondii or Klebsiella 
pneumoniae infection, as mice deficient in the receptor for IL-17 (IL-17RA
-/-
) mice had 
decreased survival (59, 110). 
 
1.4.6 Cell biology of neutrophil mobilization by G-CSF 
As discussed above, the GCSFR is expressed primarily on hematopoietic cells but also on 
some stromal cell types (42, 43).  These data suggest that G-CSF may act on either 
stromal cells or hematopoietic cells to induce neutrophil mobilization.  Work by Dr. 
Craig Semerad in our laboratory utilized a series of bone marrow radiation chimeras 
derived from wild-type and CSF3R
-/- 
mice to demonstrate that G-CSFR signaling in 
hematopoietic but not stromal cells is necessary to induce neutrophil mobilization from 
the bone marrow to the blood (74) (Figure 1-4A).  The G-CSFR is highly expressed on 
neutrophils; thus, it was expected that G-CSF signals acting directly on neutrophils would 
lead to their mobilization in a cell-intrinsic manner.  However, mice reconstituted with a 
mixture of wild-type and G-CSFR
-/- 
cells showed that this was not the case, as neutrophil 
release at baseline or in response to G-CSF was equivalent between the two genotypes 
(Figure 1-4B).  Of note, the number of wild-type neutrophils in the bone marrow of the 
mixed chimeras was nearly equal to the number in control chimeras transplanted with 
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wild-type cells alone because of the defects in neutrophil production in G-CSFR-deficient 
cells.  These data show that G-CSF signals in neutrophils were neither necessary nor 
sufficient for their mobilization and suggest the presence of indirect, trans-acting signals 
generated by G-CSF signaling in a non-neutrophilic hematopoietic intermediary.  Two 
such potential signals are discussed below:  proteases and CXCL12. 
 
1.4.7 Neutrophil proteases 
Neutrophils contain an array of proteases in their granules; these enzymes allow the 
neutrophil to degrade tissue and cellular debris at a site of inflammation and thereby 
contribute to the resolution of an infection.  A recent hypothesis proposes that these same 
proteases can mediate neutrophil and/or hematopoietic stem cell mobilization from the 
bone marrow by cleaving signaling, adhesion, or extracellular matrix proteins.  Evidence 
for this hypothesis shows that G-CSF treatment results in increased expression of the 
neutrophil serine proteases cathepsin G (CG) and neutrophil elastase (NE) (111).  
Furthermore, these proteases were able to cleave VCAM-1 (112), c-Kit (113), CXCL12 
(SDF-1), and its receptor CXCR4 (114), which are all molecules thought to be important 
for regulating neutrophil or stem cell release from the marrow.  Neutrophil mobilization 
by CXCL8 (IL-8) was impaired by neutralizing antibodies against MMP-9 (115).  
However, mice genetically deficient for the proteases MMP-9, both CG and NE, or DPPI 
all had normal resting neutrophil counts and normal mobilization after G-CSF treatment.  
This result was confirmed by pharmacologic inhibition of a broad spectrum of 
metalloproteinases in DPPI-deficient (CTSC
-/-
) mice, which lack the enzyme necessary 
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for the activation of all neutrophil serine proteases (116).  Together, this data shows that 
proteases are not necessary for neutrophil mobilization, or at least not mobilization by G-
CSF.  It is possible that different mobilizing agents utilize distinct mechanisms, that 
redundant mobilization pathways are involved, or that unknown proteases can provide a 
compensatory function. 
 
1.4.8 The CXCR4/CXCL12 axis provides a key retention signal 
Accumulating evidence suggests that signaling through the CXC-chemokine receptor 4 
(CXCR4) induced by its ligand, stromal-derived factor-1 (SDF-1 or CXCL12) provides a 
key retention signal regulating neutrophil release from the bone marrow.  The molecular 
and cellular biology of CXCR4 will be discussed further below.  In brief, CXCR4 is 
broadly expressed on hematopoietic cells, and CXCL12  is constitutively produced in the 
bone marrow compartment by distinct types of stromal cells as discussed below (Figure 
1-2D) (117, 118).  Mice reconstituted with CXCR4
-/-
 cells have impaired retention of 
granulocytes in their bone marrow and increased circulating neutrophils (119).  
AMD3100, specific antagonist of CXCR4 signaling, induces an increase in circulating 
neutrophils in mice and humans (120, 121).  Patients with WHIM syndrome, a disease 
characterized by mutations in CXCR4 that confer elevated sensitivity to CXCL12, have a 
severe neutropenia (122, 123).  G-CSF induced neutrophil mobilization is accompanied 
by a decrease in bone marrow CXCR4 and CXCL12 levels (74, 124, 125) (Figure 1-3 
and 1-5).  Using a series of G-CSFR mutant mice that have varying degrees of neutrophil 
mobilization in response to G-CSF treatment, our laboratory has shown that the 
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magnitude of the CXCL12 decrease is inversely correlated with mobilization (74).  
Although these data convincingly demonstrate that CXCR4 signals play a role in 
neutrophil homeostasis, the precise manner in which it acts to regulate neutrophils is 
undefined.  The specific role of CXCR4 in neutrophil homeostasis is defined in Chapter 
2 of this thesis using mice with a myeloid-specific deletion of CXCR4. 
 
1.4.9 Regulation of CXCL12 production in the bone marrow by G-CSF 
CXCL12 is produced in non-hematopoietic bone marrow stromal cells that include 
osteoblast lineage cells, endothelial cells, fibroblasts, and other cell types (118).  The 
normal phenotype in irradiated wild-type mice reconstituted with CXCL12
-/- 
cells 
confirmed that non-hematopoietic stromal cells are the source of the biologically 
important CXCL12 (126).  A number of authors have attempted to define the biologically 
important population of CXCL12-producing cells in the bone marrow (127-130).  They 
show that endothelial cells, osteoblasts, and associated reticular cells all may play a role 
in regulating CXCL12 (Figure 1-2D).  Work by Dr. Semerad and Dr. Matthew 
Christopher in our laboratory identified osteoblasts as the major producers of CXCL12 
within the bone marrow stromal cell compartment and showed that G-CSF or other 
cytokines downregulate CXCL12 secondary to suppression of osteoblast number (131-
133).  However, the bone marrow chimera data discussed above suggest that G-CSF does 
not act directly on osteoblasts.  Instead, the sum of the data suggest a model for neutropil 
mobilization where G-CSF  signaling in a subset of hematopoietic cells generates 
secondary signals that act in trans to suppress osteoblasts and CXCL12 expression 
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(Figure 1-5).  Recent, unpublished work by Dr. Christopher and others suggests that 
monocytes are the key subset of hematopoietic cells upon which G-CSF acts.  The nature 
of the secondary signals, effects of G-CSF on other stromal cell populations, and 
potential additonal (chemokine or non-chemokine) molecules important for neutrophil 
mobilization produced by (osteoblast or non-osteoblast) stromal cells need to be 
determined and are areas of active investigation in our laboratory.  Specifically, 
endothelial cells are capable of producing a wide variety of chemokines, but data on the 
properties of bone marrow endothelium are limited, as most studies have focused on 
activated endothelium in vitro or in other tissues.  Work presented in Chapter 3 of this 
thesis will address some of these questions. 
 
1.5 Regulation of neutrophil clearance 
A final regulatory step in controlling neutrophil counts is the process of neutrophil 
margination and extravasation into the tissues.  The cellular and molecular signals 
necessary for the process of neutrophil arrest on the endothelium, adherence, and 
transmigration across the vascular barrier from the blood to tissue sites of inflammation 
have been well described (91, 92) and will not be covered here.  Another aspect of 
neutrophil clearance is the investigation of where and how neutrophils are cleared under 
homeostatic conditions.  Neutrophils home to many different tissues, with the most 
prominent being the bone marrow, spleen, and liver (134).  These senescent neutrophils 
presumably undergo apoptosis and are cleared by tissue macrophages at these sites (135).  
The kinetics of clearance are rapid, with a calculated blood half life of 3-11 hours 
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depending upon the method of measurement used.  Neutrophil clearance does not depend 
upon G-CSF signals, as neutrophils in CSF3
-/-
 mice have a normal half-life (11), as did 
mice expressing the chimeric GEPOR (74).  Conversely, recent data suggests that in 
addition to its role regulating neutrophil release, CXCR4 may play a role in neutrophil 
clearance at bone marrow sites.  CXCR4 is upregulated as neutrophils age in vitro (121, 
136, 137).  CXCR4
high
 neutrophils preferentially home to the bone marrow, and this 
homing is abrogated by blocking antibodies against CXCR4 (121, 138).  CXCL12 
stimulation of CXCR4 induces TNF related apoptosis inducing ligand (TRAIL) and 
TRAIL receptors that increase the sensitivity of neutrophils to apoptosis (139).  Together, 
these data suggest that CXCR4 regulates not only neutrophil release, but neutrophil 
clearance and apoptosis as well.  However, these results must be interpreted with caution, 
as the ex vivo manipulation necessary for these experiments can activate neutrophils and 
alter their homing and apoptosis.  In Chapter 2, we demonstrate that CXCR4 mediates 
neutrophil homing to the bone marrow but it is not essential for the clearance of 
circulating neutrophils. 
 
1.6 Chemokines and regulation of neutrophil release 
1.6.1 The Chemokine System 
The name chemokine is a combination of the words chemotactic cytokine, and the 
classically described function of chemokines is indeed to direct the chemotaxis of various 
leukocyte subsets and thereby regulate their trafficking throughout the body.  
Chemokines are soluble proteins that form chemotactic gradients, and they are produced 
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by a variety of cell types.  They bind to specific receptors on the cell surface, which are 
all seven-transmembrane proteins that signal by activating heterotrimeric G proteins 
through exchange of GDP for GTP.  They can be classified into inducible or homeostatic 
groups, with the former being important for inflammatory responses and the latter being 
important for immune cell surveillance and developmental functions.  The accepted 
nomenclature for chemokines is based on the presence of a C-C, C-X-C, C-X3-C, or C-X 
amino acid motif, and they are numbered in the order of their discovery (140).  
Chemokine receptors are named similarly according to the class of chemokine they bind 
(141).  Chemokines and their receptors are implicated in the pathogenesis of numerous 
diseases with an infectious or inflammatory component, including cancer cell survival 
and metastasis (142), and have therefore been well-studied as drug targets (143). 
 
1.6.2 CXCR4/CXCL12 
CXCR4 (reviewed by Busillo and Benovic (144)) was originally discovered for its role as 
a coreceptor required for HIV-1 entry into cells, and its major ligand CXCL12 (SDF-1) 
was identified by its ability to block viral entry (145-147).  CXCL12 had previously been 
cloned from a bone marrow stromal cell line and was noted for its role in promoting B 
lymphocyte development.  CXCR4 and CXCL12 are among the most well-studied and 
unique chemokine ligand-receptor pairs.  They have a diverse array of functions in 
addition to directing leukocyte trafficking.  CXCL12 and CXCR4 are expressed in many 
sites throughout the body, including brain, thymus, heart, lung, liver, lymph node, kidney, 
spleen, stomach, intestine, and bone marrow.  As mentioned above, considerable interest 
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has been directed at defining the cell type within the bone marrow that expresses the 
CXCL12 important for regulating leukocyte and stem cell function.  Several studies have 
provided somewhat conflicting results, but in general CXCL12 expression is localized to 
sites near the endothelium or endosteum (Figure 1-2D) (103, 127-129, 131).  CXCR4 is 
present in every mature leukocyte type in addition to being expressed in more primitive 
hematopoietic cells (148).  Therefore, CXCR4 has been widely studied for its role in 
directing hematopoietic stem cell migration, a process of critical importance for the 
treatment of malignancy with stem cell transplant.  In addition to its role in HIV 
infection, CXCR4 has been implicated in the development and metastasis of various 
cancers of hematopoietic, epithelial, and neural origin (149).  Lastly, in an atypical 
function for chemokines, CXCL12 or CXCR4 is required for the appropriate 
development of the cerebellum, cardiac septum, gut vasculature, in addition to being 
necessary for development of B lymphopoiesis and myelopoiesis in the hematopoietic 
system. 
 In perhaps another indicator of their distinct properties compared to most 
chemokines, both CXCR4 and CXCL12 are highly evolutionarily conserved.  The murine 
and human orthologues of CXCL12 have 99% homology, while the CXCR4 gene is 90% 
conserved between the two species.  This is in contrast to the much lower homology of 
chemokines CCL2 (MCP-1) (55%), CCL3 (MIP-1α) (75%), or the CXCR2 receptor 
(71%).  Additionally, CXCL12 has a chromosomal location on 10q distinct from the C-X-
C chemokine cluster on 4q.  It is constitutively expressed in many tissues, while most 
other chemokines show inducible expression.  CXCR4 is located on chromosome 2q near 
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other chemokine receptor genes.  CXCL12 is thought to be the major physiologic ligand 
for CXCR4 because of their nearly identical tissue expression pattern and the fact that 
CXCL12
-/-
 and CXCR4
-/-
 mice have nearly identical phenotypes (150).  However, 
additional receptors and ligands have since been described (see below). 
The transcriptional expression of CXCR4 is regulated by a number of factors.  
Importantly for this work, CXCR4 is expressed on neutrophils (136, 138) and 
downregulated by the cytokiness IFN, GM-CSF, and G-CSF in vitro and in vivo (124, 
136).  G-CSF treatment negatively regulates the transcription of CXCR4 by inducing the 
expression of the late myeloid transcription factor GFI-1(151).  If mature neutrophils are 
shutting off their transcription of CXCR4, this may explain why bone marrow neutrophils 
have the highest CXCR4 expression and peritoneal neutrophils the lowest, with blood 
neutrophils intermediate (138).  Conversely, other studies have shown that CXCR4 is 
upregulated as neutrophils are aged in vitro (121, 137)  Other neutrophil releasing factors 
such as LPS (152) and lithium(153) have also been shown to downregulate CXCR4 
mRNA in neutrophils in vitro.  Transcriptional downregulation of CXCR4 by neutrophil 
mobilizing agents or with maturation may contribute to neutrophil release, consistent 
with the idea of CXCR4 as a retention signal.  However, the role of CXCR4 in the 
clearance of aged, senescent neutrophils is not clear.  This question will be addressed in 
Chapter 2. 
The mechanisms of CXCR4 trafficking to the cell membrane, signal transduction, 
desensitization, internalization, and degradation generally follow those described for 
GPCRs in general and are covered in the review above (Figure 1-6) (144).  However, a 
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few points merit mention.  CXCR4 exists and signals as a dimer on the cell membrane, 
transmitting signals via heterotrimeric G-proteins with a Gαi subunit.  It has also been 
shown to signal via JAK proteins and binding of β-arrestin molecules.  CXCR4 is 
degraded by agonist-induced ubiquitination by the E3 ligase AIP4 and sorting to the 
lysosome.  Additionally, its signaling upon CXCL12 binding can be desensitized by 
phosphorylation of residues on the cytoplasmic tail by G-protein receptor kinases 
(GRKs).  Some of these phosphorylated residues allow binding of β-arrestins, which then 
mediate receptor internalization.  Interestingly, in B and T lymphocytes from mice 
deficient in GRK6 or β-arrestin-2, membrane GTPase activity was increased but 
chemotaxis was severely impaired, indicating that chemotaxis in these cells was G-
protein independent but dependent on β-arrestin binding to the receptor (154).  However, 
GRK6
-/-
 neutrophils had increased chemotaxis toward CXCL12 and impaired G-CSF-
induced neutrophil mobilization, but normal basal neutrophil counts (155).  This finding 
was supported by the fact that CXCR4 lacking the entire cytoplasmic tail had impaired 
desensitization and internalization (156).  However, the cytoplasmic tail was required for 
chemotaxis, indicating that it has important signaling functions in addition to regulating 
internalization.  Desensitization and downregulation of CXCR4 through phosphorylation 
of the cytoplasmic tail by GRKs are likely to be important in regulating neutrophil 
release. 
CXCR4 signaling has diverse functions in numerous organ systems.  Mice 
genetically deficient in either CXCL12 or CXCR4 die perinatally (embryonic day 18.5 to 
~1 hour after birth) and display defective cerebellar granule cell formation, ventricular 
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septal defects, impaired blood vessel formation, and a failure to establish definitive B 
lymphopoiesis and myelopoiesis in the bone marrow (150, 157-159).  The role of 
CXCR4 signals in brain development was a novel finding, and it fits nicely with the role 
of CXCR4 as a proliferative signal in pediatric brain tumors (160).  Further studies 
showed that CXCR4 was the only chemokine receptor expressed during embryogenesis, 
and that it signaled during gastrulation (161).  Studies with radiation chimeras and further 
analysis of knockout mice confirmed CXCR4/CXCL12 signaling to have a major role in 
early B lymphopoiesis (162), T lymphocyte repopulation and development in the thymus 
(163), and retention of B lymphocytes and neutrophils in the bone marrow (119).  
CXCR4
-/-
 but not CXCL12
-/-
 hematopoietic stem cells (HSC) exhibit an engraftment 
defect in repopulating irradiated mice, indicating that CXCL12 is produced by non-
hematopoietic cells while CXCR4 is required on hematopoietic cells (126).  In agreement 
with this finding, studies of human HSC treated with blocking antibodies for CXCR4 
showed impaired NOD-SCID engraftment (164).  Additionally, through studies primarily 
in human HSC, CXCR4 signals were shown to regulate cell adhesion (165), survival 
(166), and proliferation (167) in addition to the cell migration defects apparent from 
studies of knockout mice.  Interestingly, the defect in bone-marrow colonization by long 
term HSCs in CXCL12
-/-
 embryos can be rescued by endothelial cell expression of 
CXCL12, but the reduction in myeloid cells remained (168).  This suggests that some 
other cell type in the bone marrow produces the CXCL12 important for neutrophil 
retention in the bone marrow, possibly osteoblasts as mentioned above.     
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Precise control of the level of CXCR4 signaling may be necessary for the 
appropriate chemotaxis or migration of cells.  In a zebrafish model, it has been 
demonstrated that CXCR4 is essential for appropriate germ cell migration to their target 
during development (169).  However, when a truncated CXCR4 protein that was 
defective in internalization and thus had an elevated level of signaling was expressed in 
CXCR4 deficient zebrafish embryos, the germ cells failed to arrive at the gonad despite 
normal motility and directional sensing (170).  This demonstrates that subtle alterations 
in CXCR4 signaling can affect cell migration in vivo. 
 
1.6.3 Additional receptors and ligands: CXCR7 and MIF 
Recently, an additional receptor (RDC-1) for CXCL12 has been identified.  It was 
subsequently classified as CXCR7, and it also binds CXCL11 (171).  CXCR7 is 
expressed on a specific subsets of T and B lymphocytes, endothelial cells, in fetal liver, 
and on many tumor cell lines.  Consistent with this, its expression in tumors provides a 
growth advantage (172).  It is a non-signaling receptor, unable to induce chemotaxis or 
calcium transients in response to SDF-1.  However, it can form oligomers with CXCR4, 
and it augments CXCR4 signaling as demonstrated by additive effects of blocking 
CXCR4 and CXCR7 in cells co-expressing the receptors (173).  CXCR7
-/-
 mice have 
been described, and they have normal hematopoiesis, CNS, and gut vasculature but die 
perinatally of severe heart valve defects (174).  Knockdown of CXCR7 in zebrafish also 
leads to vascular defects (172).  In the zebrafish model of germ cell migration, 
knockdown of CXCR7 leads to aberrant migration, and the authors conclude that CXCR7 
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regulates CXCL12 gradients by acting as a sink, thus decreasing CXCL12 levels (175).  
It is interesting to speculate that CXCR7 may act to regulate CXCL12 levels in the bone 
marrow or CXCR4 sensitivity on neutrophils, thus fine-tuning CXCL12 gradients and 
regulating neutrophil release during stress granulopoiesis. 
Macrophage migration inhibitory factor (MIF) has recently been identified as a 
ligand for both CXCR2 and CXCR4, and it played a role in T lymphocyte and monocyte 
recruitment into atherosclerotic plaques (176).  It is unclear what role it might have in 
neutrophil mobilization. 
 
1.6.4 CXCR2 
It is not clear how modulation of neutrophil CXCR4 signaling is linked to their migration 
toward the vascular endothelium and subsequent entry into the circulation.  Therefore, the 
question of whether neutrophil egress from the bone marrow is a passive, random process 
or actively directed and what (if any) signals regulate it remains unanswered.  Based on 
their well-characterized role in other aspects of neutrophil biology, we hypothesized that 
ELR
+
 CXC chemokines (CXCL1-3, 5-8), signaling through CXCR1 and CXCR2, oppose 
CXCL12 and direct neutrophil release from the bone marrow (141, 177).  This hypothesis 
was tested in experiments described in Chapter 3 of this thesis. 
Consistent with this idea, as immature Lin
lo
 Kit
+
 Sca
+
  (LKS) murine 
hematopoietic cells were differentiated in vitro into mature neutrophils, they upregulated 
CXCR2 expression (178).  CXCR2 ligands are also potent neutrophil mobilizing agents.  
Treatment of mice with CXCR2 ligands human CXCL2 (GROβ (179), CXCL8 (IL-8) 
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(83), murine CXCL2 (MIP-2) (99), or CXCL1 (KC) (138) results in a rapid neutrophilia 
that peaks at ~1 hour and resolves in 2-3 hours.  However, it is not clear from these 
experiments whether CXCR2 signaling plays a role in basal release or how these agents 
mediate their effects within the bone marrow compartment. 
It is important to realize that humans have two receptors, CXCR1 and CXCR2, 
for CXCL8 (IL-8), the prototypic ELR
+
 chemokine.  Both receptors are expressed on 
myeloid cells (177), and the best described functions of CXCR2 and its ligands are 
granulocyte and monocyte/macrophage specific.  ELR
+
 chemokines induce neutrophil 
accumulation at inflammatory sites by mediating a variety of steps in the process, 
including expression of adhesion molecules, transmigration across the endothelium, and 
release of proteases (141, 177).  Of note, there is only one functional IL-8 receptor in the 
murine genome, named CXCR2 because it has greater homology to human CXCR2 than 
CXCR1 (68% vs 71%) (180).  However, CXCR2 is also expressed in B lymphocytes, 
consistent with the B cell expansion observed in CXCR2
-/-
 mice (181).  Additionally, 
CXCR2 has been described to play a role in the proliferation of hematopoietic 
progenitors, mediation of cellular senescence, wound healing, and angiogenesis through 
its expression on endothelial cells (182-186). 
ELR
+
 CXC chemokines are classically produced in autocrine fashion by myeloid 
and endothelial cells to mediate leukocyte infiltration into inflamed tissue, but the 
expression of ELR
+
 chemokines in the bone marrow is poorly characterized.  CXCL2 is 
produced by a subset of Gr-1
+ 
cells in the bone marrow (187), but we did not observe 
CXCL2 mRNA in F4/80
+
 monocytes under basal or stress conditions (unpublished 
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observation).  Parathyroid hormone-stimulated osteoblasts were recently shown to 
produce CXCL1 (188). 
Surprisingly, CXCR2
-/-
 mice were first described to have a profound neutrophilia 
with a myeloid and B lymphoid expansion in the bone marrow, spleen, and lymph nodes, 
arguing against CXCR2 as a positive regulator of neutrophil release (189).  However, 
CXCR2
-/-
 mice housed in a germ-free facility have normal hematopoiesis with normal to 
decreased circulating leukocyte counts (183, 190, 191).  CXCR2
-/-
 neutrophils exhibited 
defective emigration into sites of inflammation as expected.  Taken together, these data 
suggest that chronic subclinical infection and the systemic release of cytokines that 
stimulate granulopoiesis are responsible for the unexpected phenotype in CXCR2
-/- 
mice, 
although a negative regulatory role for CXCR2 in myeloid progenitors has also been 
proposed (183).  It is also possible that CXCR2 signals are required for the neutrophil 
emigration into peripheral tissues and/or clearance by phagocytes necessary to complete 
the homeostatic feedback loop previously described (Section 1.4.5, Figure 1-3).   Of note, 
the phenotype of CXCR2
-/-
  mice is very similar to humans or mice with LAD (190).  
CXCR2 mutations have also been recently described in patients with familial 
myelokathexis (discussed below).  A bovine CXCR2 non-synonymous polymorphism that 
impaired receptor function was associated with increased mastitis, but neutrophil counts 
were not altered (192).  Despite the common features of increased infection and altered 
neutrophil homeostasis in the presence of these genetic alterations, the extent to which 
the mechanism of dysregulation is shared is not clear. 
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CXCR2 may interact with G-CSF signals to regulate neutrophil mobilization.  G-
CSF treatment increases CXCR2 expression on neutrophils (193), and G-CSFR-deficient 
neutrophils treated with CXCL8 have a number of impaired responses including lack of 
mobilization (89).  Neutrophils lacking STAT3, a key transducer of G-CSFR signals, or 
those with a G-CSFR engineered to transduce EPOR-specific signals both had reduced 
mobilization after G-CSF administration (74, 90).  However, only STAT3
-/-
 cells also 
displayed impaired responses to CXCL2.     
CXCR2 may regulate CXCR4 signaling and thereby regulate neutrophil release 
through heterologous interactions.  CXCR4 has been reported to undergo heterologous 
desensitization in response to CXCR2 stimulation (138), but another report suggests that 
CXCR1 but not CXCR2 mediates this effect (194).  Modulation of CXCR4 signaling by 
heteroligmerization with other chemokine receptors has been described, although not for 
CXCR2 in particular (174, 195).  Another recent paper showed that G-CSF, acting in a 
CXCR4 dependent manner, cooperated with CXCL1 and CXCL2 to induce neutrophil 
release from the bone marrow (196).  However, this does not distinguish whether CXCR2 
is cooperating by further abrogating CXCR4 signaling or by migrating toward the 
chemotactic gradient of its own ligand.  An alternative but not mutally exclusive 
mechanism for neutrophil mobilization could act by fine modulation of the chemokine 
gradients for CXCR4 and CXCR2 in the bone marrow to determine the relative balance 
of neutrophil retention and release.  It remains unknown what chemokines or other 
mediators, besides CXCL12, would be important for this process and what cell types 
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within the bone marrow produce these molecules.  Bone marrow chemokine production 
by stromal cells will be investigated in Chapter 3. 
CXCR2 plays an important role in scavenging ELR
+
 chemokines.  Scavenger 
receptors could alter plasma chemokine levels and thus regulate neutrophil mobilization.  
Accordingly, CXCR2
-/- 
mice had elevated levels of CXCL1 (KC) and CXCL2 (MIP-2) 
(197).  Furthermore, in transgenic mice overexpressing CXCL1, CXCR2 signaling and 
responses actually decreased because of receptor desensitization and downregulation in 
response to excessive ligand (198). 
As mentioned above, African-Americans have significantly lower neutrophil 
counts, on average, than other ethnic groups (Figure 1-1A).  “Benign ethnic neutropenia” 
is also found in up to 5% of this population and defined as a neutrophil count < 1.5 x 
10
9
/L (199).  Recently, genome wide association studies have implicated an inactivating 
polymorphism in the duffy antigen receptor (DARC) on red blood cells in this condition 
(200).  DARC is a non-signaling chemokine receptor that acts as a chemokine sink (201).  
It can bind CXCL8 and has been shown to alter plasma levels of chemokines important in 
neutrophil homeostasis (202, 203). 
It is unclear how CXCR2 would regulate neutrophil release.  Does it interact with 
CXCR4?  Does it act in a cell-intrinsic fashion or generate trans-acting signals as in the 
case of G-CSFR?  What ELR
+
 chemokine ligands for CXCR2 are important for 
neutrophil mobilization?  Does it act during both basal and stress granulopoiesis?  These 
questions will be addressed Chapter 3. 
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1.7  WHIM Syndrome 
WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome 
(reviewed by Diaz and Gulino (204)) is a rare disorder characterized by immune 
dysfunction and neutropenia, first described by Zuelzer (205).  Patients with the disorder 
experience recurrent bacterial infections and extensive verrucosis secondary to chronic 
human papillomavirus (HPV) infection (122).  The number of neutrophils in the 
peripheral blood increases during the response to infection or with G-CSF treatment, 
suggesting that the defect in granulopoiesis is not absolute.  Despite the peripheral 
neutropenia, there are bizarre but mature neutrophils found in abundance in the marrow 
of these patients (termed myelokathexis).  Accelerated neutrophil apoptosis has been 
reported in patients with myelokathexis as a potential mechanism of disease (206-208). 
WHIM syndrome is a genetically and clinically heterogenous disease, ranging 
from isolated myelokathexis to the full phenotype.  The majority of reported cases have 
an autosomal dominant inheritance pattern, while some sporadic (209, 210) or apparently 
autosomal recessive cases have been reported.  Truncating mutations in the cytoplasmic 
(carboxy-terminal) tail of the CXCR4 gene located on chromosome 2q21 have been 
identified the majority of patients tested to date, while 3 patients have a wild-type CXCR4 
open reading frame (123, 210).  One patient has been reported with isolated 
myelokathexis who carries a CXCR4 mutation (123).  As mentioned above, CXCR4 and 
CXCL12 are essential for the appropriate development of B lymphocytes and myeloid 
cells, the same cell lineages that are affected in WHIM syndrome.  The mutations found 
in patients with WHIM syndrome truncate 19 (1000CàT, R334X), 17 (1006G>T, 
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G336X), 15 (1013CàG, S338X),13 (1016-1017delCT, S339fs342X), or 10 (1027GàT, 
E343X) residues from the 46 amino acids of the cytoplasmic tail of the CXCR4 receptor, 
with the R334X mutation being the most common (123, 210, 211).   
Clinically, patients can also display variable lymphopenia and are subject to a risk 
of malignancy related to viral infection.  Two cases of B cell lymphoma, one of which 
was Epstein-Barr virus (EBV) related, and several cases of cervical dysplasia related to 
the common HPV serotypes 16 and 18 have been reported (209, 212-214).  Patients have 
an increased risk of congenital heart defects (7% vs. 0.8%), and there have been two 
reports of patients with brain tumors, one patient with skeletal abnormalities, one patient 
with recurrent herpes simplex virus infection (HSV) (204).  Again, this spectrum of organ 
system involvement fits nicely with the known defects in CXCR4-, CXCR7-, or 
CXCL12- deficient mice.  Overall, mortality from WHIM syndrome is low but it carries 
significant morbidity; in the literature, one patient has died of sepsis, one from EBV-
related lymphoma, and one from glioblastoma.  For example, one middle aged patient 
was reported to have been hospitalized for severe infectious episodes over 80 times (215, 
216). 
CXCR4 constructs lacking the cytoplasmic tail have been shown to enhance 
production of inositol phosphate, prolong ligand-stimulated release of intracellular 
calcium, and decrease CXCL12-induced internalization while cell-surface expression and 
CXCL12 binding remains normal (156).  A cell line expressing the R334X mutation 
showed increased calcium flux and chemotaxis in response to CXCL12, suggesting 
abnormal, gain-of-function signaling by the mutant receptor (123, 217).  The autosomal 
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dominant inheritance pattern of WHIM syndrome also suggests a gain-of-function 
mutation.  In patient samples normal cell surface expression of CXCR4 and increased 
leukocyte chemotaxis to CXCL12 was observed.  Several reports suggest that impaired 
CXCL12-induced CXCR4 internalization and desensitization acting in a dominant 
negative manner could be responsible for the altered response to CXCL12 and the 
clinical abnormalities (210, 218).  However, another group reports no impaired 
internalization or increased calcium flux in patient cells (211).  If WHIM mutations do 
cause CXCR4 internalization and desensitization defects, presumably it is due to lack of 
phosphorylation sites for GRKs and subsequently impaired β-arrestin binding.  Viral 
expression of the R334X mutant in human CD34+ cells followed by transplant into 
NOD-SCID mice led to impaired neutrophil release in vivo (219).  Because CXCR4 has 
been implicated in regulation of cell survival, other investigators have suggested that the 
gain-of-function signaling may lead to increased neutrophil apoptosis (206).   
 
1.7.1 Wild-type CXCR4 in WHIM syndrome patients 
A puzzling and intriguing aspect of WHIM syndrome is the identification of patients with 
the full clinical phenotype and impaired desensitization and internalization of CXCR4 
who nonetheless have no CXCR4 mutations (210).  This suggested the possibility of 
alterations in molecules that regulate CXCR4 expression and function.  This possibility 
was confirmed in a recent report that demonstrated that impaired GRK3 production or 
function played a key role in mediating increased CXCR4 signaling in patients with 
WHIM syndrome (220).  However, no mutations in GRK3 were present, suggesting that 
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alterations in GRK3 a binding partner or other gene silencing mechanisms exist in these 
patients.  In contrast to data in mice indicating that GRK6 and β-Arrestin regulate 
CXCR4 signaling in neutrophils (155), GRK6 and β-Arrestin function appeared to be 
normal in these patients.  Of note, GRK3 is highly expressed in normal leukocytes 
including neutrophils (221).  GRK3
-/-
 mice exist (222), but there is no analysis of their 
hematopoiesis in the literature. 
The potential basis of disease in a second family with autosomal recessive 
isolated myelokathexis (123, 215) and a wild-type CXCR4 gene has recently been 
brought to our attention by our collaborator Dr. George A. Diaz (O’Shaughnessy, A.L., 
Sun, Q., Diaz, G.A., manuscript in preparation).  These patients carry homozygous 
968delA mutations in CXCR2 (IL8Rβ), a chemokine receptor specifically expressed on 
neutrophils.  The mutation results in H323fs6X truncation of the carboxy terminal 
cytoplasmic tail of the receptor.  However, the consequences of this truncation mutation 
are quite different than for CXCR4 truncation mutations.  The CXCR2 mutation results in 
the loss of a F-X6-IL motif that is conserved in many GPCRs and required for export 
from the endoplasmic reticulum (223).  When expressed in cell lines, the mutant CXCR2 
appears to be functionally null.  There is no cell surface expression, and 
immunofluorescence experiments showed accumulation of the protein in the endoplasmic 
reticulum.  The effect of this mutation in vivo or studies of patient leukocytes were not 
reported.  It is unclear how CXCR2 interacts with CXCR4 to regulate neutrophil release, 
or how loss of CXCR2 signals could lead to disease in these patients.  These questions 
will be addressed in Chapter 3. 
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Figure 1-1.  Neutrophil counts and mortality.  Cumulative incidence of neutrophil 
counts in a sample of (A) 25,000 US Americans separated by race or (B) different inbred 
strains of mice (n = 15-30 per strain). (C)  Relationship between mortality and white 
blood cell count (WBC).  The dashed lines represent the 95% confidence interval.  
Modified from von Vietinghoff and Ley (5) and Ruggiero et al (7).  Panel A and B:  
Copyright 2008.  The American Association of Immunologists, Inc.  Panel C reprinted 
with permission from the American College of Cardiology.  Mouse data originally 
obtained from The Jackson Laboratory Mouse Phenome Database at 
www.jax.org/phenome. 
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Figure 1-2.  Microanatomy of the bone marrow vasculature.  (A) Schematic  diagram 
of the trilaminar structure of the bone marrow sinus wall showing the discontinuous 
adventitial cell and basal membrane layers and the endothelium with openings known as 
diaphragmed fenestrae (DF).  (B) Electron micrographs demonstrating the passage of 
neutrophils (arrow) though endothelial cells (arrowheads) and into the lumen of the bone 
marrow venous sinus.  (C) Fetal bone marrow endothelium shown by CD31 (PECAM-1) 
staining demonstrates the normal pattern of blood vessels into which neutrophils 
produced in the extravascular space must migrate.  The dashed line shows the 
approximate location of the endosteum.  (D)  Co-localization of some CD31+ cells with 
CXCL12 (SDF-1) producing cells in fetal bone marrow.  Modified from Petrides and 
Dittman (panel A) (68), Furze and Rankin (panel B) (224), and Ara et al (panels C and 
D) (168).  Reprinted with permission from Elsevier.  
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Figure 1-3.  Homeostatic control of neutrophils via a feedback loop involving 
cytokines and chemokines.  See text for further details.  In brief, tissue macrophages 
and dendritic cells phagocytose transmigrated neutrophils, which downregulates their 
constitutive production of IL-23.  IL-23 stimulates production of IL-17 by T lymphocyte 
subsets, which in turn positively regulates serum G-CSF levels.  G-CSF induces 
neutrophil release by down regulating CXCL12/CXCR4 signaling.  Data presented in this 
thesis indicates that CXCR2 also mediates G-CSF induced neutrophil release and 
possibly neutrophil transmigration and subsequent dampening of IL-23 production.  
Modified with permission from Christopher and Link (13). 
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Figure 1-4.  Mechanisms of neutrophil mobilization by G-CSF.  (A)  Irradiated wild-
type mice were reconstituted with G-CSFR-deficient hematopoietic cells (left panel) or 
vice versa (right panel).  In the stromal model, G-CSF signaling in non-hematopoietic 
cells is sufficient for neutrophil mobilization, while in the right panel G-CSF signaling in 
hematopoietic cells is required for neutrophil release into the blood.  (B)  Next, chimeric 
mice were generated with a mixture of wild-type and G-CSFR-deficient hematopoietic 
cells.  On the left, cell-intrinsic G-CSF signals induce neutrophil release, while the trans 
model predicts that G-CSF regulates secondary signals that mobilize neutrophils 
independently of G-CSF signaling.  Experimental data are consistent with the right 
panels.  Shaded cells, G-CSFR-deficient.  Figure modified with permission from a review 
by Link (225).   
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Figure 1-5.  Multi-step model of G-CSF-induced neutrophil mobilization.  CXCL12 
signaling through CXCR4 normally retains neutrophils in the bone marrow, thus 
inhibiting their mobilization.  G-CSF leads to neutrophil mobilization by inhibiting 
CXCL12/CXCR4 signaling through direct inhibition of CXCR4 expression and indirect 
suppression of CXCL12 production by osteoblasts.  G-CSF signaling in monocytes 
decreases osteoblast number by yet to be determined pathways.  Given their key 
anatomic position in the physical process of neutrophil mobilization, endothelial cells are 
likely to play a role that is currently undefined.  
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Figure 1-6.  Signal transduction pathways and regulation of CXCR4.  CXCL12 
binding to CXCR4 leads to the activation of multiple G protein-dependent signaling 
pathways, resulting in diverse biological outcomes such as migration, adhesion, and 
transcriptional activation.  Pathways activated and outcomes elicited may differ between 
CXCR4+ cell types.  Two potential G protein-independent pathways have been 
described.  Tyrosine phosphorylation of CXCR4 results in the recruitment and activation 
of the JAK/STAT pathway, while p38 and ERK activation has been shown to be partially 
dependent on arrestin-3 (β-arrestin-2).  Following activation, GRK phosphorylation 
results in the recruitment of arrestin 2/3 (β-arrestin 1/2) and subsequent internalization.  
CXCR4 is also ubiquitinated by AIP4 at the plasma membrane, which results in its 
sorting to and degradation in lysosomes.  However, a portion of the internalized receptor 
may also recycle back to the plasma memebrane.  Reprinted from a review by Busillo 
and Benovic (144) with permission from Elsevier. 
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Chapter 2 
 
 
CXCR4 is a key regulator of neutrophil release from the bone 
marrow under basal and stress granulopoiesis conditions 
 
 
 
 
The research in this chapter was originally published in Blood. 
 
Eash KJ, Means JM, White DW, and Link DC.  CXCR4 is a key regulator of neutrophil 
release from the bone marrow under basal and stress granulopoiesis conditions.  Blood.  
2009; 113(19):  4711-4719.  © the American Society of Hematology. 
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2.1 Abstract 
The number of neutrophils in the blood is tightly regulated to ensure adequate protection 
against microbial pathogens while minimizing damage to host tissue.  Neutrophil 
homeostasis in the blood is achieved through a balance of neutrophil production, release 
from the bone marrow, and clearance from the circulation.  Accumulating evidence 
suggests that signaling by CXCL12, through its major receptor CXCR4, plays a key role 
in maintaining neutrophil homeostasis.  Herein, we generated mice with a myeloid 
lineage-restricted deletion of CXCR4 to define the mechanisms by which CXCR4 signals 
regulate this process.  We show that CXCR4 negatively regulates neutrophil release from 
the bone marrow in a cell autonomous fashion.  However, CXCR4 is dispensable for 
neutrophil clearance from the circulation.  Neutrophil mobilization responses to 
granulocyte colony stimulating factor (G-CSF), CXCL2, or Listeria monocytogenes 
infection are absent or impaired, suggesting that disruption of CXCR4 signaling may be a 
common step mediating neutrophil release.  Collectively, these data suggest that CXCR4 
signaling maintains neutrophil homeostasis in the blood under both basal and stress 
granulopoiesis conditions primarily by regulating neutrophil release from the bone 
marrow. 
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2.2 Introduction 
Neutrophils play an essential role in the innate immune response, as they are required to 
effectively protect the host against a variety of bacterial and fungal pathogens.  Under 
basal conditions, the great majority of neutrophils reside in the bone marrow.  In response 
to infection or other stresses, this pool of neutrophils can be mobilized into the blood, 
providing the host with a mechanism to rapidly increase neutrophil delivery to sites of 
infection.  It is essential that neutrophil number in the blood be tightly regulated.  
Persistent neutropenia is associated with profound immunodeficiency, while excessive 
neutrophil infiltration and activation contributes to tissue damage in certain inflammatory 
disorders, such as rheumatoid arthritis.  Neutrophil homeostasis is maintained through a 
balance of neutrophil production, release from the bone marrow, and clearance from the 
circulation (1).  Contributing to the complexity of this process, neutrophils have the 
shortest survival of any circulating cell, with reported half-lives of 8-16 hours under basal 
conditions (2-7).  Despite its importance, the mechanisms regulating neutrophil number 
in the blood are incompletely understood.   
 Accumulating evidence suggests that the chemokine CXCL12 (stromal derived 
factor-1, SDF-1), through interaction with its major receptor CXCR4, plays a key role in 
controlling neutrophil homeostasis (8).  Mice deficient for CXCL12 or CXCR4 die 
perinatally, but the fetal circulation is characterized by elevated numbers of neutrophils 
and a failure to establish bone marrow myelopoiesis (9-12).  In CXCR4
-/-
 fetal liver 
chimeras, mature neutrophils and granulocytic precursors are increased in the blood, 
while the number of mature neutrophils in the bone marrow is reduced (13, 14).  Humans 
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and mice treated with AMD3100, a selective antagonist of CXCR4, or CXCR4 blocking 
antibodies display a rapid mobilization of neutrophils into the blood (15-17).  Truncation 
mutations of CXCR4 that cause increased receptor signaling are responsible for most 
cases of WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) syndrome, 
which is characterized by abnormal retention of neutrophils in the bone marrow (18-20).  
Importantly, CXCR4 is expressed by neutrophils as well as most other hematopoietic 
cells, and CXCL12 is constitutively expressed at high levels in the bone marrow stroma 
(21, 22).  Together, these data support a model in which CXCL12 signaling through 
CXCR4 provides a key retention signal for neutrophils in the bone marrow and therefore 
negatively regulates their release. 
 As noted previously, peripheral blood neutrophil counts can increase rapidly in 
response to infection or other stress.  A wide variety of infectious agents, bacterial 
products, cytokines, and chemokines are thought to contribute to this “emergency” or 
“stress” granulopoiesis response (23, 24).  The downstream signals that regulate this 
response are relatively undefined, but recent evidence suggests that CXCR4 may play a 
role.  Treatment with granulocyte colony-stimulating factor (G-CSF), a key cytokine in 
the stress granulopoiesis response, results in a decrease in CXCL12 expression in the 
bone marrow and the downregulation of CXCR4 expression on neutrophils (25-28).  
These observations suggest the hypothesis that disruption of CXCR4 signaling is a key 
step mediating neutrophil release by G-CSF.  Whether disruption of CXCL12/CXCR4 
signaling is a common mechanism by which other mobilizing agents increase neutrophil 
counts in the blood is unknown. 
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 Neutrophil homeostasis in the blood is determined, in part, by the rate of 
clearance from the circulation.  Neutrophils are cleared primarily in the liver, spleen, or 
bone marrow, where apoptotic or aged neutrophils are thought to be phagocytosed by 
macrophages (17, 29, 30).  Recent studies suggest that CXCR4 may play a role the 
clearance of aged, senescent neutrophils, particularly at bone marrow sites.  CXCR4 
expression increases on neutrophils as they age, and blocking antibodies to CXCR4 
impede neutrophil homing to the bone marrow (17, 31).  Thus, CXCR4 may have a dual 
role in regulating neutrophil homeostasis by acting as a signal clearing senescent 
neutrophils from the blood in addition to regulating neutrophil release. 
 The broad expression of CXCR4 on hematopoietic cells complicates the analysis 
of this gene during granulopoiesis.  For example, CXCR4
-/- 
fetal liver chimeras display 
defects in multiple hematopoietic lineages, including hematopoietic stem cells (13, 14, 
32).  Therefore, in the present study we use transgenic mice carrying a myeloid specific 
deletion of CXCR4 to further define the role of CXCR4 in basal and stress 
granulopoiesis.  Using this system, we show that CXCR4 is dispensable for neutrophil 
clearance from the blood.  In contrast, CXCR4 is required for neutrophil mobilization 
from the bone marrow in response to G-CSF, CXCL2 (growth regulated gene β, GROβ), 
or Listeria monocytogenes infection.  These results suggest that CXCR4 signaling is an 
essential regulator of neutrophil homeostasis under both basal and stress granulopoiesis 
conditions.   
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2.3 Methods 
2.3.1 Mice.  The LysM
Cre
 and CXCR4
+/-
 mice (12, 33) were obtained from The Jackson 
Laboratory (Bar Harbor, ME) and conditional CXCR4 (CXCR4
flox/flox
) (34) mice were 
obtained from Dr. Dan R. Littman (New York University).  All mice were inbred onto a 
C57BL/6 background at least 10 generations. Mice were genotyped by PCR as described 
(12, 33, 34).  Congenic wild-type C57BL/6 mice (B6.SJL-Ptprc* Pep3b BoyJ, The 
Jackson Laboratory) that have the Ly 5.1 gene were used to facilitate analysis of chimeric 
mice.  Sex- and age-matched mice between 6 and 16 weeks of age were used in 
accordance with the guidelines of the Washington University Animal Studies Committee. 
 
2.3.2 CXCR4 genotyping.  Peripheral blood neutrophils (Gr-1
bright
SSC
hi
) from 
CXCR4
flox/-
 or LysM
Cre/+
 CXCR4
flox/-
 mice were isolated using a MoFlo high-speed cell 
sorter (Dako, Carpinteria, CA).  Genomic DNA was prepared using the ArchivePure 
DNA kit (5Prime, Gaithersburg, MD).  The presence of either a floxed or deleted CXCR4 
allele was revealed by PCR amplification using the listed primers.  Floxed: 5'-
CCACCCAGGACAGTGTGACTC TAA-3' and 5'-
GATGGGATTTCTGTATGAGGATTAGC-3' Deleted: 5'-TCTAACGTCCCA 
GATCCACC-3' and 5'-AACCAAACAAACCATCACACAG-3'.  
 
2.3.3 Blood, bone marrow, or spleen analysis. Blood, bone marrow, and spleen cells 
were harvested from mice using standard techniques, and the number of nucleated cells in 
these tissues quantified using a Hemavet automated cell counter (CDC Technologies, 
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Oxford, CT).  In some cases, manual leukocyte differentials were performed on Wright-
stained blood smears (minimum 100 cells) or bone marrow cytospins (minimum 300 
cells).  As reported previously,(26) the percentage of total body neutrophils in the blood 
was estimated using the neutrophil distribution index (NDI), which is calculated by 
dividing the number of neutrophils in the blood by the number in the blood and bone 
marrow.  Blood and bone marrow neutrophils were calculated assuming a blood volume 
of 1.8 ml and a whole femur equivalent to 6% of the total bone marrow (35).   
 
2.3.4 Flow cytometry.  Cells from bone marrow, blood, or spleen were depleted of red 
cells by hypotonic lysis, resuspended in phosphate-buffered saline (PBS) supplemented 
with 0.2% bovine serum albumin (BSA) and 0.1% sodium azide (FACS buffer), 
incubated for 10 minutes with anti-CD16/32 (Fc-block, BD Biosciences, San Diego, CA) 
and stained for 20-30 minutes at 4°C with one or more of the following antibodies as 
described in the text:  allophycocyanin (APC)-conjugated anti-Ly6G (Gr-1, 
Invitrogen/Caltag, Carlsbad, CA), biotinylated anti-CXCR4 (eBioscience, San Diego, 
CA), biotinylated anti-CD115 (GM-CSFR, eBioscience), PerCP-Cy5.5-conjugated anti-
CD3e (BD Biosciences), PerCP-Cy5.5-conjugated anti-Ly5.1 (CD45.1, BD Biosciences), 
fluorescein (FITC)-conjugated anti-Ly5.2 (CD45.2, eBioscience), Alexa488-conjugated 
anti-F4/80 (Invitrogen), and APC-Alexa750-conjugated anti-CD45R (B220, Invitrogen).  
Biotinylated antibodies were detected with phycoerythrin (PE)-conjugated streptavidin 
(eBioscience).   Isotype-matched antibodies and unstained cells were used as negative 
controls.  Mature neutrophils were gated as Gr-1
hi
SSC
hi
 cells, and in some experiments 
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F4/80 or CD115 was used to further exclude blood monocytes. Data was collected on a 
FACScan 5-color, 2-laser flow cytometer (BD Biosciences and Cytek Development, 
Fremont, CA) using Cellquest software (BD Biosciences) and analyzed with the Flowjo 
software package (Tree Star, Ashland, OR). 
 
2.3.5 Colony-forming cell assay. Twenty µl of blood, 1 x 10
5
 nucleated spleen cells, or 
2 x 10
4
 bone marrow cells were plated in 2.5 ml methylcellulose media supplemented 
with a cocktail of recombinant cytokines (MethoCult 3434, Stemcell Technologies, 
Vancouver, BC, Canada) or 10 ng/ml recombinant human G-CSF (M3231, Stemcell 
Technologies).  Cultures were plated in duplicate and placed in a humidified chamber 
with 6% CO2 at 37°C.  Colonies containing at least 50 cells were counted on days 7-10 of 
culture. 
 
2.3.6 Bone marrow transplantation.  Wild type (Ly5.1) or LysM
Cre/+
 CXCR4
flox/-
 
(Ly5.2) bone marrow cells were harvested.  A total of 2 million bone marrow cells were 
mixed at a 1:1 ratio and injected retroorbitally into lethally irradiated wild type mice 
(Ly5.1).  Recipient mice were conditioned with 1,000 cGy from a 
137
Cesium source at a 
rate of approximately 95 cGy/min prior to transplantation.  Prophylactic antibiotics 
(trimethoprim-sulfamethoxazole, Alpharma, East Bridgewater, NJ) were given during the 
initial 2 weeks following transplantation.  Mice were analyzed 8-10 weeks after 
transplantation. 
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2.3.7 BrdU labeling.  Bromodeoxyuridine (BrdU, 10 mg/ml solution in 1x Dulbecco’s 
PBS, Sigma, St. Louis, MO) was given by a single intraperitoneal injection at a dose of 1-
2 mg/mouse. The percentage of BrdU
+
/Gr-1
+
 cells was determined by staining with APC-
conjugated Gr-1 antibody followed by fixation, permeablization, and intracellular 
staining with a FITC-conjugated anti-BrdU antibody using reagents from the BrdU Flow 
kit (BD Biosciences). The half-life (t1/2) of neutrophils in the blood was calculated using 
the formula N = N0e
-λt
 where N0 = the peak number of labeled cells, N = the number of 
cells at time t and λ = the decay constant. 
 
2.3.8 Adoptive transfer experiments.  Bone marrow cells were harvested, red blood 
cells removed by hypotonic lysis at room temperature for 2 minutes, and 8-10 x 10
6
 cells 
injected intravenously into unconditioned wild type (Ly5.1) recipients. Bone marrow 
cells were harvested 1.5 to 2.5 hours after infusion, and donor neutrophils were identified 
based on Gr-1
 
and Ly5.2 expression.  The absolute number of donor neutrophils in the 
bone marrow was calculated assuming a whole femur equivalent to 6% of the total bone 
marrow (35). This number was divided by the total number of donor neutrophils that 
were infused to yield the percentage of donor neutrophils that had homed to the bone 
marrow.   
 
2.3.9 Neutrophil mobilization.  G-CSF:  recombinant human G-CSF, a generous gift 
from Amgen (Thousand Oaks, CA), was diluted in PBS with 0.1% low endotoxin BSA 
(Sigma) and administered by twice daily subcutaneous injection at a dose of 125 
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μg/kg/day for 5 days.  Mice were analyzed 3-4 hours after the final injection on day 5.  
Some cohorts of mice were given a single subcutaneous injection of G-CSF (125 μg/kg), 
and peripheral blood was analyzed at the indicated times. 
GROβ:  human GROβ, a generous gift from Genzyme (Cambridge, MA), was 
reconstituted in sterile PBS and administered as a single subcutaneous injection at a dose 
of 100 μg/kg.  Peripheral blood was analyzed at the indicated times. 
 
2.3.10 Listeria monocytogenes infection.  Mice were infected intraperitoneally with a 
dose of 5 x 10
5
 colony forming units (c.f.u) of L. monocytogenes strain EGD.  Peritoneal 
cells were obtained by lavage with 10 ml of cold PBS, nucleated cells counted, and 
manual leukocyte differential counts (200 cells) performed on Wright-stained cytospins.  
At 72 hours, L. monocytogenes was quantified by homogenizing the spleens and livers in 
10 ml PBS with 0.05% Triton X-100 and plating serial dilutions on LB-agar. 
 
2.3.11 Statistical analysis.  Statistical significance was assessed using a two-tailed 
Student t test assuming equal variance for comparison of two groups, one-way ANOVA 
with Bonferroni post-testing for experiments with more than two groups, or, for time-
course experiments, a 2-way ANOVA with Bonferroni post-testing at individual time 
points.  All data are presented as the mean ± SEM. 
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2.4 Results 
2.4.1 CXCR4 is selectively deleted in myeloid cells of LysM
Cre/+
 CXCR4
flox/-
 
(MKO) mice 
Mice expressing Cre-recombinase under the control of the myeloid lysozyme M promoter 
(LysM
Cre
) were crossed with CXCR4
+/-
 and CXCR4
flox/flox
 mice to generate myeloid-
restricted knockout (MKO) mice with the genotype LysM
Cre/+
 CXCR4
flox/-
.  Efficient 
deletion of CXCR4 in mature neutrophils (Gr-1
bright
SSC
hi
) of MKO mice in both the 
blood and bone marrow was observed by flow cytometry.  Whereas CXCR4 expression 
was easily detectable in wild type neutrophils in the blood, no expression was detected in 
MKO neutrophils (Figure 2-1 A & B).  CXCR4
+/-
 mice had intermediate levels of 
CXCR4 expression on their neutrophils.  There was some residual expression of CXCR4 
in MKO bone marrow neutrophils, possibly representing less mature myeloid cells that 
had not yet undergone Cre-mediated excision of CXCR4.  As expected, expression of 
CXCR4 was normal to slightly reduced in B lymphocytes and T lymphocytes from MKO 
mice compared to wild type mice (Figure 2-1A and data not shown).  PCR analysis of 
genomic DNA isolated from MKO blood neutrophils confirmed complete Cre-mediated 
excision of the coding region of exon 2 of the CXCR4 gene (Figure 2-1C). These data 
show that CXCR4 is efficiently and specifically deleted in myeloid cells in MKO mice. 
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2.4.2 Loss of CXCR4 results in the redistribution of neutrophils from the bone 
marrow to blood 
To assess the effect of the loss of CXCR4 on basal granulopoiesis, MKO or control mice 
housed in standard pathogen free conditions were analyzed.  We initially analyzed 4 
separate control groups: wild type mice, CXCR4
flox/+
 mice, LysM
Cre/+
 CXCR4
+/+ 
mice, and 
CXCR4
+/-
 mice.  The wild type, CXCR4
flox/+
, and LysM
Cre/+
 CXCR4
+/+
mice had similar 
phenotypes for all assays and were subsequently pooled as control mice (Figure 2-2 and 
data not shown).  MKO mice displayed a marked isolated neutrophilia in the peripheral 
blood (Figure 2-2A).  The number of Gr-1
bright
SSC
hi
 cells (neutrophils) in the blood was 
1.7 ± 0.2 x 10
6
/ml in control mice versus 8.5 ± 0.4 x 10
6
/ml in MKO mice (p < 0.0001).  
This increase in circulating neutrophils was confirmed by manual inspection and 
differential counts of blood smears [absolute neutrophil count: 1.6 ± 0.4 x 10
6
/ml (control 
mice) versus 5.3 ± 0.7 x 10
6
/ml (MKO mice); p < 0.001].  Interestingly, no increase in 
immature myeloid cells in the blood was observed (data not shown).  MKO mice 
displayed normal numbers of circulating B lymphocytes and T lymphocytes (data not 
shown).  They also had normal numbers of circulating and splenic hematopoietic 
progenitor cells as measured by colony forming assays (data not shown). 
In the bone marrow of MKO mice, the number of Gr-1
bright
SSC
hi
 cells was 
reduced to 71.8 ± 2.9% of control mice (Figure 2-2B).  Although the Gr-1
bright
SSC
hi
 cell 
population reliably measures mature neutrophils in the blood, this population is more 
heterogeneous in the bone marrow with approximately 20% immature myeloid cells (36).  
Thus, to confirm these findings, we also performed manual leukocyte differentials of 
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bone marrow cells (Figure 2-3).  Consistent with the flow cytometry data, a trend to 
decreased band and segmented neutrophils in the bone marrow of MKO mice was 
observed (control, 6.3 ± 0.9 x 10
6
/femur versus MKO, 4.2 ± 1.0 x 10
6
/femur; p = 0.14).  
Of note, the frequency of granulocytic precursors and number and cytokine 
responsiveness of myeloid progenitors was comparable in MKO and control mice 
(Figures 2-3 & 2-4), suggesting that neutrophil differentiation was normal.   
Neutrophil trafficking from the bone marrow was estimated by determining the 
percentage of neutrophils in the blood versus the total number of neutrophils in the bone 
marrow and blood (26).  Consistent with previous reports, in control mice, only 1.9 ± 
0.2% of neutrophils are in the blood.  Strikingly, in MKO mice, this percentage increased 
to 11.9 ± 1.2% (Figure 2-2C; p < 0.0001).  There also was a significant increase in 
splenic neutrophils in MKO mice [number of neutrophils per spleen:  4.3 ± 1.3 x 10
6
 
(control) versus 13.3 ± 1.8 x 10
6
 (MKO); p < 0.01]. Collectively, these data suggest that 
the loss of CXCR4 results in the redistribution of neutrophils from the bone marrow to 
the blood and spleen. 
 
2.4.3 Loss of CXCR4 results in premature release of neutrophils from the bone 
marrow but normal clearance from the blood 
An increase in circulating neutrophil number could be caused by increased production of 
neutrophils in the bone marrow, increased release into the blood, decreased clearance 
from the blood, or some combination thereof.  To investigate differences in kinetics of 
neutrophil release into the blood and the potential difference in neutrophil survival, 
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control or MKO mice were given a single injection of bromodeoxyuridine (BrdU) to 
label newly synthesized neutrophils. The fate of blood neutrophils pulse-labeled with 
BrdU in vivo was determined by flow cytometry for Gr-1
+
BrdU
+ 
cells (Figure 2-5A).
 
 In 
the bone marrow, a similar percentage of myeloid cells were labeled with BrdU, 
suggesting that loss of CXCR4 does not affect granulocytic cell proliferation (data not 
shown).  Consistent with a role for CXCR4 in regulating neutrophil release, the transit 
time for labeled neutrophils to appear in the circulation was significantly reduced in 
MKO
 
mice.  In control mice, the peak number of labeled neutrophils in the blood 
occurred 72 hours after BrdU administration, while in the majority of MKO mice, the 
peak was at 46 hours (Figure 2-5B).  However, there was no significant difference in the 
disappearance of labeled cells from the blood.  Consistent with previous studies in mice 
and humans, the calculated half-life of control neutrophils was 13.7 ± 2.3 hours.  A 
similar calculated half-life was observed for MKO neutrophils (10.0 ± 1.0 hours, Figure 
2-5C).  Taken together, these data show that neutrophils lacking CXCR4 have accelerated 
release from the bone marrow but normal clearance from the blood. 
 
2.4.4 CXCR4 directs homing of neutrophils to the bone marrow 
Previous studies suggested that aged neutrophil preferentially home to, and are cleared in, 
the bone marrow in a CXCR4-dependent fashion (17, 31).  To test this possibility, we 
measured the trafficking of neutrophils to the bone marrow after adoptive transfer of 
control or MKO neutrophils into wild type recipient mice.  Donor neutrophils from 
control mice were clearly detectable in recipient bone marrow 1.5-2.5 hours after 
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transfer.  However, homing of MKO neutrophils to the bone marrow was significantly 
reduced, although not eliminated completely (Figure 2-6).  These data confirm that 
CXCR4 contributes to neutrophil homing to the bone marrow.  However, given the 
normal circulating half-life of endogenous MKO neutrophils, it appears that the bone 
marrow is not an essential site of neutrophil clearance.  
 
2.4.5 CXCR4 acts in a cell autonomous fashion to retain neutrophils in the bone 
marrow 
Recent studies suggest that loss of adhesion molecules on neutrophils may result in 
neutrophilia in a non-cell autonomous fashion through disruption of a homeostatic 
feedback loop (37, 38).  To determine whether CXCR4 acts in a cell autonomous fashion 
to regulate neutrophil release, mixed bone marrow chimeras were generated in which 
hematopoiesis was reconstituted with a 1:1 ratio of wild type to MKO cells. The mixed 
chimeras displayed chronic neutrophilia (absolute neutrophil count of 5.8 ± 0.4 x 
10
6
/mL).  Whereas the percentage of wild type and MKO neutrophils in the bone marrow 
was similar, the great majority of neutrophils in the blood were derived from MKO cells 
(Figure 2-7A).  Accordingly, the calculated neutrophil distribution index for MKO cells 
(23.9 ± 2.5%) was much higher than that for wild type neutrophils (4.3 ± 0.6%; p < 
0.0001; Figure 2-7B).  As a control, we also assessed the distribution of B lymphocytes in 
the mixed chimeras.  Though a modest increase in MKO-derived B lymphocytes was 
observed, the ratio of MKO to wild type cells in the bone marrow and blood was similar 
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(Figure 2-7C). These data show that CXCR4 negatively regulates neutrophil release in a 
cell autonomous fashion. 
 
2.4.6 Neutrophil mobilization by G-CSF or GROβ is impaired in the absence of 
CXCR4 
A key feature of the innate immune response is the capacity to rapidly increase neutrophil 
number in the blood in response to infection or other stresses.  Certain cytokines, 
chemokines, and bacterial products are thought to mediate the stress granulopoiesis 
response.  To examine the contribution of CXCR4 signaling in stress granulopoiesis, we 
first characterized the neutrophil response to G-CSF, the prototypical mobilizing 
cytokine.  Following a single injection of G-CSF, neutrophil number in the blood of 
control mice increased 3.9 ± 0.7 fold (Figure 2-8A), with peak levels occurring after 6 
hours before returning to near-baseline levels at 24 hours.  As reported previously (25), 
this was associated with a marked decrease in surface CXCR4 expression on blood 
neutrophils (Figure  2-8B).  In contrast, no change in neutrophil counts in the blood was 
observed after G-CSF treatment of MKO mice (Figure 8A).  Next, we studied 
granulopoiesis after 5 days of G-CSF administration.  In control mice, an 11.8 ± 1.6 fold 
increase in circulating neutrophils was observed (Figure 2-8C).  This increase was 
secondary to both increased production (as evidenced by a modest increase in bone 
marrow neutrophils) and increased neutrophil release (as evidenced by an increase in the 
NDI).  Of note, previous studies showed that G-CSF does not alter the kinetics of 
neutrophil clearance from the blood (2, 3, 26).  In MKO mice, a similar increase in bone 
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marrow neutrophils after G-CSF treatment was observed, suggesting that G-CSF induced 
increases in neutrophil production were intact.  In contrast, though a modest increase in 
circulating neutrophils was observed in MKO mice after G-CSF treatment, this appears to 
be mainly secondary to increased production, rather than release, as no increase in the 
NDI was seen.  
We also examined neutrophil release after treatment with GROβ, a well-
characterized mobilizing chemokine.  In control mice, GROβ treatment induced a 7.4 ± 
2.1 fold increase in circulating neutrophils that peaked 30 minutes after injection and 
nearly returned to baseline after two hours (Figure 2-8D).  In contrast, no significant 
increase in circulating neutrophils was observed in MKO mice.  Surprisingly, CXCR4 
expression on neutrophils isolated from control mice treated with GROβ was 
significantly reduced at the time of peak mobilization compared to pre-treatment levels 
(Figure 2-8E).   These data suggest that G-CSF and GROβ induced neutrophil release 
from the bone marrow are dependent on CXCR4 signals. 
 
2.4.7 Neutrophil mobilization in response to Listeria monocytogenes infection is 
impaired in the absence of CXCR4 but homing of neutrophils to the peritoneum and 
bacterial clearance is normal 
To further define the requirement for CXCR4 in emergency granulopoiesis, control and 
MKO mice were infected intraperitoneally with Listeria monocytogenes.  Infection with 
L. monocytogenes is an established model of emergency granulopoiesis, and neutrophils 
are known to play a key role in the clearance of this infection (39).  Clearance of bacteria 
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was similar in MKO and wild type mice; no difference in survival or spleen and liver 
bacterial load was observed after L. Monocytogenes challenge (Figure 2-9 A & B).  In 
control mice, a 3.4 ± 0.6 fold increase in circulating neutrophils was observed 24 hours 
after bacterial challenge that remained elevated for the duration of the assay.  In contrast, 
MKO mice failed to increase their circulating neutrophils in response to infection with 
this pathogen (Figure 2-9C).  However, neutrophils in MKO mice were able to emigrate 
into the peritoneal space in similar numbers compared to control mice (Figure 2-9D).  
These data show that CXCR4, while required for maximal neutrophil mobilization into 
the blood after L. monocytogenes infection, is dispensable for neutrophil emigration to 
the peritoneum. 
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2.5 Discussion 
There is accumulating evidence suggesting that CXCR4 is a key regulator of neutrophil 
homeostasis.  Perhaps most convincing is the identification of truncation mutations of 
CXCR4 in most cases of WHIM syndrome.  Patients with WHIM syndrome display 
neutropenia despite normal to increased numbers of neutrophils in the bone marrow. The 
CXCR4 truncation mutations confer enhanced responsiveness to CXCL12, suggesting a 
model in which increased CXCR4 signaling in WHIM neutrophils results in their 
abnormal retention in the bone marrow (18, 19, 40, 41).  Consistent with this model, 
treatment of humans or mice with AMD3100, a specific CXCR4 antagonist, results in the 
rapid mobilization of neutrophils into the blood (15, 16).  However, direct testing of the 
contribution of CXCR4 to neutrophil homeostasis has been limited by the embryonic 
lethality of CXCR4 deficient mice and the severe engraftment defect of CXCR4
-/-
 
hematopoietic stem cells (10, 11, 13, 32).  In the present study, we characterized 
granulopoiesis and neutrophil trafficking in transgenic mice carrying a myeloid-specific 
deletion of CXCR4.  The marked neutrophilia present in these mice confirm a key role 
for CXCR4 signaling in the regulation of neutrophil homeostasis.   
Neutrophil homeostasis in the blood is maintained by balancing neutrophil 
production, release from the bone marrow, and clearance.  There is evidence implicating 
CXCR4 in the regulation of all three of these processes.  In WHIM syndrome, there are 
reports of dysmorphic neutrophils and increased neutrophil apoptosis, suggesting 
defective granulopoiesis (42, 43).  Moreover, in CXCR4
-/-
 fetal liver chimeras, there is a 
decrease in myeloid progenitors and precursors (13).  Our study was not designed to 
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assess the contribution of CXCR4 to granulopoiesis, since CXCR4 expression in MKO 
mice was maintained until the final stages of myeloid development.  Not surprisingly, 
granulopoiesis, as measured by leukocyte differentials, BrdU incorporation in myeloid 
precursors, and number and cytokine responsiveness of myeloid progenitors, was normal 
in MKO mice.  Despite normal granulopoiesis, marked neutrophilia and increased splenic 
neutrophils were observed in MKO mice, suggesting an alteration in neutrophil release or 
clearance.   
As noted previously, the rapid mobilization of neutrophils into the blood by 
AMD3100 suggests a role for CXCR4 in regulating neutrophil release.  Indeed, the 
striking redistribution of neutrophils from the bone marrow to blood in MKO mice 
suggests enhanced neutrophil release.  Consistent with this conclusion, BrdU labeled 
neutrophils appeared in the blood more rapidly in MKO versus control mice.  A recent 
report suggested that CXCR4 may contribute to neutrophil clearance from the blood by 
directing senescent neutrophils to the bone marrow (31).  Consistent with this finding, we 
observed decreased homing of CXCR4
 
deficient neutrophils to the bone marrow after 
adoptive transfer.  On the other hand, the half-life of CXCR4 deficient neutrophils in the 
blood was comparable to wild type neutrophils, suggesting that CXCR4 is not a major 
regulator of neutrophil clearance from the blood and that the bone marrow represents a 
non-essential site of neutrophil removal. Collectively, these data suggest that CXCR4 
maintains neutrophil homeostasis primarily by regulating neutrophil release from the 
bone marrow.   
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Neutrophil homeostasis can be regulated in both a cell autonomous and non-cell 
autonomous fashion.  In a series of elegant studies, Stark and colleagues showed that β2-
integrin deficient
 
neutrophils induced neutrophilia in a non-cell autonomous fashion 
through the suppression of a negative feedback loop that senses the number of 
neutrophils that have emigrated into the tissue (37, 38).  They showed that the presence 
of even a small number of wild type neutrophils activated the feedback loop and restored 
normal neutrophil number in the blood.  In contrast, we observed persistent neutrophilia 
and preferential release of CXCR4 deficient neutrophils in mixed bone marrow chimeras 
reconstituted with both wild type and MKO bone marrow cells.  These data show that 
CXCR4 acts in a cell autonomous fashion to regulate neutrophil release from the bone 
marrow.   
 G-CSF, the prototypical neutrophil mobilizing cytokine, is key regulator of both 
basal and stress granulopoiesis (44).  Previous studies have shown that treatment with G-
CSF results in a decrease in CXCL12 expression in the bone marrow (26-28).  Moreover, 
G-CSF treatment leads to decreased surface expression of CXCR4 on neutrophils, a 
finding confirmed in the present study (25).  These data suggest the hypothesis that 
disruption of CXCR4 signaling may contribute to G-CSF induced neutrophil 
mobilization.  However, G-CSF treatment also induces other changes in the bone marrow 
microenvironment, such as the release of proteases (45), that might contribute to 
neutrophil mobilization.   Thus, the relative importance of CXCR4 signaling in mediating 
neutrophil mobilization by G-CSF is unclear.  In the present study, we show that G-CSF, 
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though stimulating neutrophil production, did not stimulate neutrophil release from the 
bone marrow in the absence of CXCR4 signals.  
Of note, despite the near normal number of morphologically mature neutrophils in 
the bone marrow, it is possible that the mobilizable pool of neutrophils in MKO mice is 
exhausted.  Arguing against this possibility, blood neutrophil counts in MKO mice 
doubled after the administration of a solution of propylene glycol (data not shown).  
Collectively, these data suggest that disruption of CXCL12/CXCR4 signaling is the 
dominant pathway by which G-CSF induces neutrophil mobilization.   
Besides G-CSF, there are a number of neutrophil mobilizing agents that are 
thought to contribute to the stress granulopoiesis response.  Most notable among these 
agents are chemokines.  The rapidity of neutrophil mobilization by chemokines (minutes 
to hours) compared with G-CSF (hours to days) suggests distinct mechanisms of 
mobilization.  Consistent with this idea, the CXCR2-chemokine KC (CXCL1) can 
synergize with G-CSF or AMD3100 to induce neutrophil mobilization (17, 31, 46).  
Surprisingly, herein we show that GRO -induced neutrophil mobilization is abrogated in 
MKO mice.  This result suggests two possibilities: 1). The GRO -mobilizable pool of 
neutrophils is depleted in MKO mice.  2). GRO -induced mobilization is dependent on 
CXCR4 signaling in neutrophils.  In support of the latter possibility, several recent 
reports showed that treatment of wild type neutrophils or monocytes with CXCR2 ligands 
resulted in impaired CXCR4 signaling, presumably through heterologous desensitization 
(17, 47).  In addition, we observed a significant decrease in cell-surface CXCR4 
expression on neutrophils after GRO treatment.  Together, these data suggest that 
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disruption of CXCL12/CXCR4 signaling is a common mechanism by which chemokines 
and cytokines induce neutrophil release. 
The stress granulopoiesis response to infection requires the coordinated 
expression of many different cytokines and chemokines.  In this study, we utilized a 
model of L. monocytogenes infection to further explore the contribution of CXCR4 
signals in the stress granulopoiesis response.  Interestingly, the neutrophil mobilization 
response in MKO mice following L. monocytogenes infection was abrogated, suggesting 
that modulation of CXCR4 signaling may be a common mechanism of neutrophil release.  
In summary, our data provide new evidence that CXCR4 is a key regulator of 
neutrophil homeostasis under basal and stress conditions.  CXCR4 signals act primarily 
to regulate neutrophil trafficking from the bone marrow, and disruption of CXCR4 
signals may represent a common mechanism by which cytokines and chemokines induce 
neutrophil release from the bone marrow.  These data suggest that pharmacologic agents 
that modulate CXCR4 signaling may be effective for controlling neutrophil responses in 
infectious and inflammatory diseases.
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2.8 Figures and figure legends 
 
 
 
 
Figure 2-1.  CXCR4 is efficiently deleted in neutrophils from LysM Cre/+ CXCR4flox/- 
(MKO) mice.  (A) Representative histograms showing cell surface CXCR4 expression in 
the mature neutrophil (Gr-1brightSSChi) population from bone marrow or peripheral blood 
or the peripheral blood B lymphocyte (B-220+) population in wild type (WT) or MKO mice.  
The isotype control (ISO) is shown in gray.  (B) Cell surface CXCR4 expression in the 
mature neutrophil population in the bone marrow or peripheral blood.  Data represent the 
mean ± SEM.  #p < 0.05 compared to wild type mice.  *p < 0.05 compared to CXCR4+/- 
mice.  (C) Genomic DNA was isolated from MKO or control (CXCR4flox/- without LysMCre) 
blood neutrophils and the CXCR4 gene amplified using primers that specifically detected 
the deleted (CXCR4∆), floxed (CXCR4flox), or null (CXCR4-) CXCR4 alleles. 
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Figure 2-2.  Basal granulopoiesis in MKO mice is characterized by a shift of 
neutrophils from the bone marrow to the blood.  (A & B) The number of mature 
neutrophils (Gr-1brightSSChi) in the blood and bone marrow was quantified by flow 
cytometry in mice of the indicated genotype.  (C) The neutrophil distribution index (NDI) 
was calculated to estimate the percentage of total body neutrophils in the blood, using 
the following formula: NDI = blood neutrophils / (blood + bone marrow neutrophils).  Data 
represent the mean ± SEM.  #p < 0.05 compared to all other groups. 
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CTL 8.0 ± 1.9% 14.9 ± 1.2% 15.8 ± 3.0% 18.4 ± 2.8% 29.3 ± 4.0% 12.1 ± 1.3% 1.6 ± 0.1%
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Figure 2-3.  Morphologically mature neutrophils are present in the bone marrow of 
MKO mice.  (A) Representative micrographs of bone marrow cytospins from two 
different MKO mice or a wild type (WT) mouse demonstrating the presence of band and 
segmented neutrophils.   Original magnification x1000.  Images were acquired using an 
E plan 100x/1.25 NA oil immersion objective, Microphot SA microscope, Digital Sight 
DS-Fi1 camera, and NIS-Elements F2.30 software, all from Nikon (Melville, NY).  (B) 
Manual leukocyte differential counts were performed on control (CTL) or MKO mice.  
Data represent the mean ± SEM (n = 3 mice per group). 
93 
 
 
Figure 2-4.  MKO mice have normal numbers of myeloid progenitors in the bone 
marrow.  Bone marrow cells from control (CTL) or MKO mice were plated in 
methylcellulose medium in the presence of stem cell factor, IL-3, IL-6, and EPO (CFU-C) 
or G-CSF (CFU-G) and colonies enumerated on day 7-10 of culture.  Data represent the 
mean ± SEM (n = 5 mice per group). 
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Figure 2-5.  Blood neutrophil half-life in MKO mice is normal.  BrdU (2 mg) was 
administered to control (CTL) or MKO mice by a single intraperitoneal injection.  
Peripheral blood was obtained at the indicated time points and the number of BrdU+ Gr-
1bright  cells determined by flow cytometry.  (A) Representative dot plots showing BrdU 
staining in the Gr-1bright (mature neutrophil) population.  The numbers shown indicate the 
percentage of Gr-1bright cells that were BrdU+.  (B) The absolute number of BrdU+ Gr-
1bright neutrophils in the blood is shown.  (C) Neutrophil half-life (t1/2) in the blood was 
calculated according to the formulas t1/2 = ln 2/λ and nt = n0e
-λt where n0 is the number at 
a given time, nt is the number t hours later, and λ is the decay constant.  The data shown 
represent the mean ± SEM of n = 10-11 mice in each group.  *p < 0.05 compared to 
control mice at the same time point.  ns, not significant. 
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Figure 2-6.  MKO neutrophils have impaired homing to the bone marrow.  Bone 
marrow cells (8-10 x 106) from control (CTL) or MKO mice carrying the Ly 5.2 allele were 
adoptively transferred to WT recipients carrying the Ly 5.1 allele, enabling detection of 
infused neutrophils in the bone marrow by flow cytometry using an allele-specific CD 
45.2 antibody.  (A) Representative dot plots showing donor neutrophils as the 
percentage of total bone marrow neutrophils 1.5-2.5 hours after infusion.  (B) The 
percentage of transferred control or MKO neutrophils present in the bone marrow of 
recipient mice.  Data represent the mean ± SEM of n = 8-12 recipients for each genotype 
from 3 separate experiments.  *p < 0.05 compared to control neutrophils. 
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Figure 2-7.  Trafficking of MKO neutrophils is altered in mixed chimeras.  Whole 
bone marrow from wild type (WT, Ly5.1) and MKO (Ly5.2) mice was mixed in a 1:1 ratio 
and transplanted into lethally irradiated wild type (Ly5.1) recipients.  After hematopoietic 
reconstitution (8-10 weeks), the bone marrow and blood were analyzed by flow 
cytometry.  The numbers at the top of the columns indicate the fold increase over the 
wild type cells.  (A) Mature neutrophils (Gr-1bright CD115-).  (B) Neutrophil distribution 
index.  (C) B lymphocytes (B220+).  The data represent the mean ± SEM of n = 18 
recipients from two separate transplants.  *p < 0.05 compared to wild type cells. 
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Figure 2-8.  Neutrophil mobilization by G-CSF or GROβ is abrogated in MKO mice.  
(A) Mice (n = 5 per group) were given a single subcutaneous injection of G-CSF (125 
μg/kg) and the absolute neutrophil count measured at the indicated times.  †p < 0.05 
compared to time 0.  (B) Representative histograms showing cell surface CXCR4 
expression on blood neutrophils from control (CTL) or MKO mice at baseline and 65 
minutes after a single dose of G-CSF (+G).  (C) Mice (n = 8-11 per group) were treated 
with G-CSF (125 μg/kg/day, twice daily injections) for 5 days, and neutrophils in the 
bone marrow and blood were quantified.  The calculated neutrophil distribution index is 
shown in the far right panel.  *p < 0.05 compared with control mice at the same time 
point.  #p < 0.05 compared to untreated mice of the same genotype.  (D) Mice (n = 9-12 
per group) were given a single subcutaneous injection of GROβ (100μg/kg), and the 
absolute neutrophil count was determined at the indicated times.  †p < 0.05 compared to 
time 0.  (E) CXCR4 cell surface expression on peripheral blood neutrophils from control 
mice was determined by flow cytometry at baseline and at the time of peak mobilization, 
30 minutes after GROβ administration.  **p < 0.001.  Data represent the mean ± SEM. 
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Figure 2-9.  MKO mice have impaired blood neutrophil mobilization but normal 
neutrophil recruitment to the peritoneum in response to Listeria infection.  Control 
(CTL) or MKO mice  were infected intraperitoneally with Listeria monocytogenes.  (A) 
Survival was assessed in mice (n = 12 per group) from two separate infections with 9.8 
to 11.2 x 105 C.F.U. of bacteria.  (B) The bacterial titer in the spleen and liver of control 
and MKO mice (n = 8 per group) was determined 72 hours after infection with 2.1 to 7.2 
x 105 C.F.U. of bacteria.  (C) Blood neutrophil counts were assessed by flow cytometry at 
the indicated times after infection with 2.1 to 9.8 x 105 C.F.U. of bacteria (n = 8-19 mice 
per group depending on the time).  (D) Shown is the number of neutrophils in the 
peritoneum at the indicated times after infection with 2.1 to 7.2 x 105 C.F.U. of bacteria (n 
= 5-8 mice per group depending on the time).  Data represent the mean ± SEM.  †p < 
0.05 compared to time 0. 
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Chapter 3 
 
 
CXCR2 and CXCR4 antagonistically regulate neutrophil 
trafficking from the bone marrow 
 
 
 
This chapter has been published and is reproduced with permission from the American 
Society for Clinical Investigation. 
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3.1 Abstract 
Neutrophil homeostasis is maintained, in part, by the regulated release of neutrophils 
from the bone marrow.  Constitutive expression of the chemokine CXCL12 by bone 
marrow stromal cells provides a key retention signal for neutrophils in the bone marrow 
through activation of its receptor CXCR4.  Herein, we show that the ELR
+
 chemokines 
CXCL1 and CXCL2 are constitutively expressed by bone marrow endothelial cells and 
osteoblasts, and CXCL2 expression is induced in endothelial cells during G-CSF-induced 
neutrophil mobilization.  Neutrophils lacking CXCR2, the receptor for CXCL1 and 
CXCL2, are preferentially retained in the bone marrow, reproducing a myelokathexis 
phenotype.  Transient disruption of CXCR4 failed to mobilize CXCR2
-/-
 neutrophils.  
However, doubly deficient neutrophils (CXCR2
-/-
 CXCR4
-/-
) displayed constitutive 
mobilization, showing that CXCR4 plays a dominant role.  Collectively, these data 
suggest that CXCR2 signaling is a second chemokine axis that interacts antagonistically 
with CXCR4 to regulate neutrophil release from the bone marrow.   
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3.2 Introduction 
Neutrophils are an essential component of the innate immune response and a major 
contributor to inflammation.  Accordingly, the number of neutrophils in the blood is 
tightly regulated.  Neutrophil homeostasis is maintained through a balance of neutrophil 
production, release from the bone marrow, and clearance from the circulation (1).  The 
bone marrow is the primary site of neutrophil production, requiring that mature 
neutrophils transmigrate through an endothelial cell barrier to enter the circulation (2-4).  
Under basal conditions, less than 2% of the total body of mature neutrophils are in the 
circulation (5).  Thus, the bone marrow serves as a reservoir for neutrophils that can be 
rapidly mobilized in response to infection or other stresses.   
Major advances in our understanding of the mechansims regulating neutrophil 
release from the bone marrow have come from the study of the human disease 
myelokathexis (kathexis = retention) (6-8).  Myelokathexis is characterized by 
neutropenia despite normal to increased numbers of neutrophils in the bone marrow.  It 
can occur in isolation or as a component of WHIM (warts, hypogammaglobulinemia, 
infections, myelokathexis) syndrome (WS) (9, 10).   Genetic studies have shown that 
heterozygous mutations of CXCR4 are the most common cause of WHIM syndrome (11).  
CXCR4 encodes for a CXC chemokine receptor whose major ligand is CXCL12 (SDF-1) 
(12).  WHIM-associated mutations of CXCR4 result in the production of a carboxy-
terminal truncated receptor that displays impaired  internalization and enhanced 
signaling, suggesting that excessive CXCR4 signaling may result in abnormal neutrophil 
retention in the bone marrow (13-16).  Conversely, genetic deletion of CXCR4 in murine 
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hematopoietic cells results in constitutitive mobilization of neutrophils into the blood (17-
22).   Moreover, treatment of humans or mice with AMD3100, a small molecule 
antagonist of CXCR4, causes rapid neutrophil mobilization (23, 24).  Together with the 
observation that CXCL12 is constituitively expressed at a high level by bone marrow 
stromal cells (25), these data indicate that the CXCR4/CXCL12 axis provides a key 
retention signal for neutrophils in the bone marrow.  
Disruption of CXCR4 signaling is an important mechanism by which neutrophils 
are mobilized into the circulation under stress conditions.  Treatment with G-CSF, a 
major mobilizing cytokine, is associated with decreased CXCL12 expression in the bone 
marrow and decreased CXCR4 expression on neutrophils (5, 26-28).  Yet, the 
mechanisms by which attenuated CXCR4 signaling leads to migration of neutrophils 
towards the bone marrow venous sinuses and subsequent entry into the circulation are 
unclear.  Based on their well-characterized role in other aspects of neutrophil biology 
(29), we hypothesized that ELR
+
 CXC chemokines may direct neutrophil migration 
towards the bone marrow vascular space, thereby opposing the CXCR4/CXCL12 axis.  
There are 7 ELR
+
 CXC chemokines (CXCL1-3, 5-8) that signal through CXCR1 or 
CXCR2 (12).  These chemokines are potent neutrophil chemoattractants and activators 
and induce neutrophil mobilization from the bone marrow when administered 
exogenously (4, 30-33).  Accordingly, CXCR2
-/-
 mice have a profound defect in 
neutrophil emigration to sites of inflammation (mice lack CXCR1) (34).  With respect to 
neutrophil homeostasis, CXCR2
-/-
 mice housed under specific pathogen free (SPF) 
conditions display neutrophilia with a myeloid expansion in the bone marrow and spleen.  
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In contrast, under gnotobiotic conditions, the level of circulating neutrophils in CXCR2
-/-
 
mice is normal, raising the possibility that subclinical infections are inducing a stress 
granulopoiesis response (35-37).   
In the present study, we generated mixed bone marrow chimeras reconstituted 
with wild type and CXCR2
-/-
 cells to study the cell-intrinsic role of CXCR2 in neutrophil 
trafficking.  We show that CXCR2
-/-
 neutrophils are selectively retained in the bone 
marrow, reproducing a myelokathexis phenotype.  CXCR2 is required for neutrophil 
mobilization in response to transient CXCR4 inhibition, although the increased release of 
CXCR4
-/-
 neutrophils is not altered in the absence of CXCR2 signals.  CXCR2 ligands 
CXCL1 (KC) and CXCL2 (MIP-2) are constitutively expressed in bone marrow 
endothelium, and CXCL2 expression is induced during G-CSF-induced neutrophil 
mobilization. These results suggest that CXCR2 signaling is a second chemokine axis 
that controls neutrophil release from the bone marrow by opposing CXCR4 signals. 
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3.3 Methods 
3.3.1 Mice. Sex- and age-matched, congenic C57BL/6 CXCR2
-/-
 (34, 38) (The Jackson 
Laboratory, Bar Harbor, ME), LysM
Cre/+ 
CXCR4
flox/-
 (22), pOBCol2.3-GFP (39), and 
wild-type mice that have the Ly5.1 gene (B6.SJL-Ptprc* Pep3b BoyJ, Jackson Labs) were 
maintained under SPF conditions according to methods approved by the Washington 
University Animal Studies Committee.  All transgenic strains had been backcrossed at 
least 10 generations onto a C57BL/6 background. 
 
3.3.2 Bone marow transplantation. Bone marrow cells from wild-type (Ly5.1
+
) mice 
and either CXCR2
-/-
, CXCR4-MKO (LysM
Cre/+ 
CXCR4
flox/-
), or DKO (LysM
Cre/+ 
CXCR2
-/- 
CXCR4
flox/-
) mice (Ly5.2
+
) were mixed at a 1:1 ratio, and a total of 2 million cells injected 
retroorbitally into lethally irradiated (1,000 cGy) wild type (Ly5.1
+
) recipient mice.  
Antibiotics (trimethoprim-sulfamethoxazole, Alpharma, East Bridgewater, NJ) were 
given for 2 weeks post-transplant. 
 
3.3.3 Blood, bone marrow, or spleen analysis. Blood, bone marrow, and spleen cells 
were quantified using a Hemavet automated cell counter (CDC Technologies, Oxford, 
CT).  Absolute neutrophil numbers were calculated assuming a blood volume of 1.8 ml 
and a whole femur equivalent to 6% of the total bone marrow (40).  Bone marrow 
extracellular fluid was obtained by sequentially flushing both femurs with 400 μL ice-
cold PBS and harvesting the supernatant after pelleting cells by centrifugation at 400 x g 
for 2 minutes. 
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3.3.4 Flow cytometry. Cells were stained by standard protocols with the following 
antibodies (eBiosciences, San Diego, CA unless otherwise noted):  Chimerism was 
assessed using PerCP-Cy5.5-Ly5.1 (CD45.1) and allophycocyanin (APC)-Ly5.2  and one 
or more of the following lineage markers: FITC-Ly6G (Gr-1, myeloid), PE-CD3e (T 
lymphocytes), and APC-efluor780-CD45R (B220, B lymphocytes). A lineage cocktail of 
FITC-conjugated Gr-1, B220, CD3e, and Ter119 (erythroid) was used to sort progenitor 
cells.  CXCR4 expression was assessed by incubating with anti-CD16/32 (Fc-block, BD 
Biosciences, San Diego, CA) and biotin-conjugated CXCR4 (BD) followed by PE-
streptavidin.  Isotype-matched antibodies were used as negative controls.  Data was 
collected on a FACScan 5-color, 2-laser flow cytometer (BD Biosciences and Cytek 
Development, Fremont, CA) using Cellquest software (BD) and analyzed with the 
FlowJo software package (Tree Star, Ashland, OR). 
 
3.3.5 Bone marrow leukocyte morphology. Gr-1
+
 Ly5.1
+
 (wild-type) or Ly5.2
+
 
(CXCR2
-/-
) bone marrow cells were isolated using a Reflection high speed cell sorter (i-
Cyt, Champaign, IL).  Manual leukocyte differentials were performed in a blinded 
fashion on Wright-stained cytospins prepared by cytocentrifugation of 200,000 sorted 
cells at 400 rpm for 4 minutes.  Photomicrographs were acquired using an E plan 
100x/1.25 NA oil immersion objective, Microphot SA microscope, Digital Sight DS-Fi1 
camera, and NIS-Elements F2.30 software, all from Nikon (Melville, NY) and 
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conversion from color to black and white was done using Photoshop CS3 (Adobe 
Systems, San Jose, CA) .   
 
3.3.6 Colony-forming cell assay. Lineage
low
 Ly5.1
+
 (wild-type) or Ly5.2
+
 (CXCR2
-/-
) 
bone marrow cells were isolated using a Reflection high speed cell sorter, and 350 (CFU-
C) or 3,000 (CFU-G) sorted cells were plated in 2.75 mL methylcellulose media 
supplemented with a cocktail of recombinant cytokines or 10 ng/mL recombinant human 
G-CSF (MethoCult 3434 or 3231, respectively; Stemcell Technologies, Vancouver, BC).  
Duplicate cultures were incubated at 37°C for 14 days, after which colonies containing at 
least 100 cells were counted in a blinded fashion. 
 
3.3.7 Neutrophil mobilization.  Recombinant human G-CSF was administered by twice 
daily subcutaneous injection at a dose of 125 μg/kg/day for 5 days.  Mice were analyzed 
3-4 hours after the final injection on day 5.  AMD3100 (Sigma, Saint Louis, MO) or 
recombinant human GROβ, was administered as a single subcutaneous injection at doses 
of 5 mg/kg and 100 μg/kg, respectively.  Peripheral blood was obtained within 90 
minutes prior to and 1-2 hours after the first injection.   
 
3.3.8 Stromal cell chemokine expression profiling. Groups of 10 Col2.3-GFP or wild-
type mice were either left untreated or given G-CSF or vehicle for 7 days as indicated.  
To isolate stromal cells, femurs were serially digested with collagenase (Worthington 
Biochemical, Lakewood, NJ) as previously reported (41, 42).  Stromal cells were then 
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incubated with APC-CD45, APC-Ter119,  and PE-CD31 (PECAM-1).  7-Amino-
Actinomycin D (7AAD) was used to exclude non-viable cells.  An average of 20,000 
cells was sorted directly into TRIZOL LS reagent (Invitrogen, Carlsbad, CA), and RNA 
was isolated according to the manufacturer’s instructions.  RNA was amplified, 
processed, and hybridized to Affymetrix (Santa Clara, CA) MOE430v2.0 GeneChip 
microarrays per protocols of the Siteman Cancer Center Multiplexed Gene Analysis Core 
Facility (Saint Louis, MO, http://pathology.wustl.edu/research/multiplexed.php).  After 
passing quality control, array data was normalized, annotated, and deposited at the 
Siteman Cancer Center Bioinformatics Core Facility (http://bioinformatics.wustl.edu) 
according to standard protocols.  Expression data for all known chemokines, obtained 
from at least 4 independent cell sorting experiments, was analyzed and compared using 2-
way ANOVA. 
 
3.3.9 CXCL2 ELISA. Quantification of CXCL2 protein in bone marrow extracellular 
fluid was performed using a commercially available enzyme-linked immunosorbent assay 
(ELISA) kit from Peprotech (Rocky Hill, NJ) according to the manufacturer’s 
instructions. 
 
3.3.10 Statistical analysis. Significance was determined using Prism software 
(Graphpad, La Jolla, CA) to perform two-tailed Student t tests assuming equal variance 
or, where indicated, 1- or 2-way ANOVAs with Bonferroni post-testing.   All data are 
presented as the mean ± SEM.  
108 
 
3.4 Results 
3.3.1 Absence of  CXCR2 results in abnormal retention of neutrophils in the bone 
marrow. 
Consistent with previous reports (34, 37), we observed marked neutrophilia in CXCR2
-/-
 
mice maintained under SPF conditions (absolute neutrophil count:  4.63 ± 1.58 x 10
9
/L 
compared with 0.69 ± 0.06 x 10
9
/L for congenic wild-type mice, P = 0.04).  To determine 
whether this phenotype was due to a cell intrinsic effect of a loss of CXCR2 signaling, 
mixed bone marrow chimeras were generating by transplanting a 1:1 ratio of wild-type 
and CXCR2
-/-
 bone marrow cells into irradiated congenic mice (Figure 3-1A).  Blood 
neutrophil counts in the CXCR2
-/-
 mixed chimeras were reduced in comparison to mice 
reconstituted with wild-type cells alone (1.08 ± 0.08 x 10
9
/L and 1.81 ± 0.29 x 10
9
/L, 
respectively; P = 0.003), suggesting that the neutrophilia in CXCR2
-/- 
mice is the result of 
a cell-extrinsic mechanism. 
In the mixed chimeras, the number of CXCR2
-/-
 neutrophils in the blood was 
reduced compared to that in the bone marrow (Figure 3-1B, C).   Whereas 65.3 ± 7.6% of 
neutrophils in the bone marrow were derived from CXCR2
-/-
 cells, only 25.0 ± 3.5% of 
neutrophils in the blood were from CXCR2
-/-
 cells (P < 0.0001).  Of note, the number of 
neutrophils in the spleen, another reservoir for neutrophils, was comparable between 
CXCR2
-/-
 and wild type cells (Figure 3-1C).  Neutrophil trafficking from the bone 
marrow was estimated by calculating the percentage of neutrophils in the blood relative 
to the total number of neutrophils in the blood, bone marrow, and spleen (neutrophil 
distribution index or NDI) (5).  Consistent with previous studies (22, 43), under basal 
109 
 
conditions 1.84 ± 0.32 % of wild-type neutrophils were present in the blood (Figure 3-
1D).  In contrast, the percentage of CXCR2
-/-
 neutrophils in the blood was only 0.57 ± 
0.18% (P = 0.02).  No perturbation in other hematopoietic lineages was observed (Figure 
1E).  The number and cytokine responsiveness of myeloid progenitors in the bone 
marrow were comparable between wild-type and CXCR2
-/-
 cells (Figure 3-1F). 
Myelokathexis is characterized by the accumulation of mature, often 
hypersegmented or dysplastic, neutrophils in the bone marrow (10).  Consistent with this 
phenotype, we observed that the percentage of Gr-1
hi
 SSC
hi
 cells, representing the most 
mature neutrophils (44), relative to the total Gr-1
+
 myeloid cell population was higher for 
CXCR2
-/-
 cells compared with wild-type cells (Figure 3-2A, B).  To confirm this finding, 
CXCR2
-/-
 and wild-type Gr-1
+
 myeloid cells were sorted from the bone marrow of the 
mixed chimeras, and manual leukocyte differentials were performed.  CXCR2
-/-
 cells 
showed an increase in the proportion of highly segmented, occasionally dysplastic 
appearing, neutrophils (Figure 3-2C, D).  Collectively, these data show that CXCR2 
deficiency results in a myelokathexis-like phenotype with a cell-intrinsic retention of 
neutrophils in the bone marrow. 
 
3.4.2 Neutrophil mobilization by G-CSF is impaired in the absence of CXCR2. 
Since it is the principal cytokine regulating emergency granulopoiesis (45), we next 
measured the short-term (1-2 hour) and long-term (5 day) neutrophil responses to G-CSF 
in the CXCR2
-/-
 mixed chimeras.  Consistent with previous reports (5, 22), administration 
of G-CSF resulted in a 2.3 ± 0.5-fold increase in the blood of wild-type neutrophils 
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within two hours (Figure 3-3A).  In contrast, there was no significant increase in CXCR2
-
/-
 neutrophils.  After the full 5-day course of G-CSF, a significant increase in both wild-
type and CXCR2
-/-
 neutrophils in the blood and spleen was observed in the mixed 
chimeras (Figure 3-3B, C).  Neutrophil release, as measured by the NDI, increased in 
response to 5 day G-CSF treatment in both genotypes (compare Figure 3-1D with Figure 
3-3D).  However, the percentage of CXCR2
-/-
 neutrophils in the blood after G-CSF 
administration was still significantly lower than that for wild-type cells. These data show 
that maximal blood neutrophil responses to G-CSF require CXCR2 signaling. 
 
3.4.3 CXCR2 antagonistically regulates CXCR4-mediated neutrophil retention in 
the bone marrow. 
Previous studies have established a dominant role for CXCR4 signals in the retention of 
neutrophils in the bone marrow (20, 22, 46-50).  Since CXCR2 signaling has been shown 
to regulate CXCR4 cell surface expression through heterologous desensitization and 
receptor internalization (48, 51), we first assessed CXCR4 expression on CXCR2
-/- 
neutrophils.  However, cell-surface expression of CXCR4 on bone marrow neutrophils 
was similar between wild-type and CXCR2
-/- 
cells (MFI: 107 ± 7 vs. 100 ± 12, 
respectively; P = 0.4; Figure 3-4A), arguing against a simple mechanism in which the 
absence of CXCR2 signals results in neutrophil retention through increased CXCR4 
expression. 
To more directly assess the relationship between CXCR2 and CXCR4 signals in 
the regulation of neutrophil trafficking, we treated mixed chimeras with AMD3100, a 
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small molecule CXCR4 antagonist.  One hour after administration of AMD3100, a 3.8 ± 
1.2-fold increase in wild-type neutrophils in the blood increased was observed (Figure 3-
4B).  In contrast, no increase in CXCR2
-/- 
neutrophils in the blood was observed, despite 
the fact that the majority of neutrophils in the bone marrow 1 hour after AMD3100 
administration were of CXCR2
-/- 
origin (Figure 3-4B, C).  Accordingly, the NDI for 
CXCR2
-/-
 cells following AMD3100 administration (0.53 ± 0.21%) was dramatically 
lower than that of wild-type cells (13.0 ± 3.27%; P = 0.02; Figure 3-4D), suggesting that 
neutrophil mobilization in response to transient CXCR4 inhibition is dependent on 
CXCR2. 
We previously reported that mice carrying a myeloid-specific deletion of CXCR4 
(MKO; LysM
Cre/+ 
CXCR4
flox/-
) displayed marked basal neutrophilia (22).  To study the 
genetic interaction of the CXCR2- and CXCR4-null alleles, we crossed CXCR4-MKO 
mice with the CXCR2
-/-
 mice to generate double knockout mice (DKO; LysM
Cre/+ 
CXCR2
-
/- 
CXCR4
flox/-
).  Similar to the CXCR2
-/-
 or CXCR4-MKO mice, DKO mice displayed 
marked neutrophilia at baseline (data not shown).  To examine the cell-intrinsic 
properties of neutrophils lacking both CXCR2 and CXCR4, mixed chimeras were 
generated as before using either DKO or, as a control, CXCR4-MKO bone marrow cells.  
Recipient mice showed the expected level of donor engraftment in the bone marrow, with 
52.1 ± 4.8% (DKO) or 62.2 ± 2.3% (CXCR4-MKO) of B lymphocytes derived from 
mutant cells.  As expected, mixed chimeras containing CXCR4-MKO cells showed a 
marked redistribution of CXCR4
-/-
 neutrophils into the blood (Figure 3-4E, F).  
Surprisingly, a similar phenotype was observed in DKO chimeras, showing that loss of 
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CXCR2 signals cannot rescue the neutrophilic phenotype of CXCR4-deficient 
neutrophils. 
To examine whether CXCR4 signals are required for mobilization by CXCR2 
ligands, CXCR4-MKO mixed chimeras were given a single injection of the CXCR2 
agonist GROβ (CXCL2).  Whereas the number of wild-type neutrophils in the blood of 
CXCR4-MKO chimeras increased 4.0 ± 0.4-fold 1 hour after GROβ administration, only 
a minimal increase in CXCR4
-/- 
neutrophils was observed, suggesting that neutrophil 
release induced by CXCR2 activation is dependent on CXCR4 (Figure 3-4G).  
Collectively, these data show that CXCR4 and CXCR2 antagonistically regulate 
neutrophil release from the bone marrow, with CXCR4 playing a dominant role.  
 
3.4.4 Expression of chemokines by osteoblasts and endothelial cells in the bone 
marrow. 
Previous studies have established that bone marrow stromal cells, in particular osteoblasts 
and endothelial cells, are the major source of CXCL12 in the bone marrow (21, 25, 27, 
42, 50, 52-54).  However, the expression of other chemokines, specifically ELR
+
 CXCR2 
ligands, in bone marrow stromal cells is unknown.  To address this issue, we analyzed 
stromal cells from the bone marrow of transgenic mice expressing GFP in osteoblast 
lineage cells (Col2.3:GFP) (39, 42).  Specifically, CD45
low
 Ter119
low 
stromal cells were 
sorted into osteoblast (GFP
+
) and endothelial (CD31
+
) fractions, which were then 
subjected to RNA expression profiling (Figure 3-5A).  Of note, expression of endothelial- 
or osteoblast-specific genes was appropriately enriched in the relevant cell fraction, 
113 
 
demonstrating the fidelity of our sorting strategy (Tables 3-1 and 3-2).  As reported 
previously (27, 42), constitutively high expression of CXCL12 was observed in 
osteoblasts and endothelial cells, with higher expression in osteoblasts (Figure 3-5B).  
The CXCR2 ligands, CXCL1 (KC) and CXCL2 (MIP-2) also were constitutively 
expressed in osteoblasts and endothelial cells, but with higher endothelial expression. 
To examine the effect of G-CSF on chemokine expression in the bone marrow 
microenvironment, endothelial cells were isolated from the bone marrow after G-CSF 
administration.  Osteoblasts were not sorted, since their number is markedly reduced by 
G-CSF (27, 41, 42, 53).  Of note, there was no change in bone marrow endothelial cell 
number (P.K.G., Christopher, M.J., A.M.G., van Os, R., D.C.L., manuscript in 
preparation).  RNA expression profiling showed that CXCL2 expression in bone marrow 
endothelial cells was induced 2.7 ± 0.3- fold by G-CSF, while CXCL12 mRNA was 
modestly reduced to 47 ± 3% of its basal level; other chemokines remained unchanged 
(Figure 3-5C).  Consistent with the mRNA data, CXCL2 protein was detected in the bone 
marrow supernatant at baseline with a trend to increased expression after G-CSF 
administration (Figure 3-5D).  Since osteoblast number is markedly reduced following G-
CSF administration, these data suggest that the balance of expression in the bone marrow 
from pro-retention (CXCL12) to mobilizing chemokines (CXCL1 and CXCL2) may 
contribute to neutrophil mobilization by G-CSF. 
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3.5 Discussion 
In the present study, we generated CXCR2
-/-
 mixed bone marrow chimeras to characterize 
the cell-intrinsic effect of CXCR2 deletion on neutrophil trafficking from the bone 
marrow.  We show that mature, occasionally hypersegmented, CXCR2
-/-
 neutrophils, are 
selectively retained in the bone marrow, reproducing a myelokathexis phenotype.  In 
contrast, CXCR2
-/- 
mice display neutrophilia, suggesting augmented neutrophil 
production and/or release.  Studies of leukocyte adhesion deficiency (LAD) mice provide 
a potential explanation for these discrepant results.  Similar to CXCR2
-/-
 mice, β2-
integrin-deficient mice (ITGB2
-/-
), which reproduce LAD type I in humans, exhibit 
impaired emigration of neutrophils from the circulation to peripheral tissues and 
neutrophilia when housed under SPF conditions (34, 55).  In a series of elegant 
experiments, Forlow et al (56) and Stark et al (57) showed that, in ITGB2
-/-
 mixed 
chimeras, as little as 10% wild-type neutrophils was sufficient to restore normal 
neutrophil homeostasis.  Moreover, they showed that neutrophil emigration into 
peripheral tissues initiated a negative feedback loop that suppresses IL-17 and G-CSF 
production.  Thus, the emigration defect shared by CXCR2
-/- 
and ITGB2
-/- 
neutrophils may 
disrupt this negative feedback loop and lead to the production of stress cytokines that 
stimulate granulopoiesis.  Consistent with this possibility, serum levels of IL-6 are 
elevated in both CXCR2
-/- 
and ITGB2
-/- 
mice (34, 55). 
Our results indicate that CXCR2 and CXCR4 coordinately regulate neutrophil 
trafficking from the bone marrow.  Previous studies have demonstrated that treatment of 
neutrophils with CXCR2 ligands results in impaired CXCR4 signaling through 
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heterologous desensitization and/or internalization (48, 51), suggesting that CXCR2 
regulates neutrophil mobilization through modulation of CXCR4 signaling and/or 
expression.  Consistent with this possibility, Martin et al (47) and others (48, 49) 
previously showed that neutrophil mobilization by the CXCR2 chemokine CXCL1 (KC) 
was markedly increased by transient CXCR4 inhibition.  Conversely, CXCR2
-/-
 
neutrophils displayed almost no mobilization in response to transient CXCR4 inhibition 
(Figure 3-4B-D).  This surprising result suggests at least two possibilities: 1) loss of 
CXCR2 may augment basal CXCR4 signaling, thereby rendering cells resistant to 
AMD3100; 2) CXCR2 signals may function independently of CXCR4 to direct 
neutrophil release following AMD3100-induced CXCR4 blockade.  In support of the first 
possibility, doubly deficient CXCR2
-/-
 CXCR4
-/-
 neutrophils display constitutive 
mobilization (Figure 3-4E, F), demonstrating that CXCR2 signals are not required for 
neutrophil mobilization in the complete absence of CXCR4 signals and suggesting a 
dominant role for CXCR4 in the regulation of neutrophil trafficking from the bone 
marrow.  Consistent with this conclusion, the present study (Figure 3-4G) and our 
previous report (22) show that neutrophil mobilization by the CXCR2 chemokine 
CXCL2 (GROβ) is impaired in the complete absence of CXCR4 signals (i.e., in CXCR4
-/- 
neutrophils).   Collectively, these data suggest that CXCR4 and CXCR2 signaling 
antagonistically regulate neutrophil release from the bone marrow. 
Previous studies have established that CXC12 is constitutively expressed by bone 
marrow stromal cells, including osteoblasts and endothelial cells (21, 25, 27, 42, 50, 52-
54).  Quantitative analysis of sorted stromal cell populations suggested that osteoblasts 
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are the major source of CXCL12 in the bone marrow (27).  Consistent with these 
findings, our RNA expression profiling of sorted bone marrow endothelial cells or 
osteoblasts demonstrated significantly higher expression of CXCL12 mRNA in 
osteoblasts.  The expression profiling data also showed that ELR
+
 CXC chemokines 
CXCL1, CXCL2, and CXCL7 are constitutively expressed in bone marrow endothelial 
cells and/or osteoblasts.  However, in contrast to CXCL12, these chemokines are 
expressed at higher levels in endothelial cells. Together, these data suggest a “tug-of-
war” model wherein endothelial-derived chemokines (primarily CXCR2 ligands) direct 
neutrophil chemotaxis toward the vasculature for entry into the circulation, while 
endosteal osteoblasts produce chemokines (primarily CXCL12) that promote neutrophil 
retention (Figure 6).  Under basal conditions, the balance of chemokine production favors 
neutrophil retention in the bone marrow.  Under stress conditions, expression of 
inflammatory cytokines, most notably G-CSF, is increased (58).  We and others 
previously showed that G-CSF administration is associated with a marked suppression of 
endosteal osteoblasts (27, 41, 42, 53).  In addition, herein we show that CXCL2 
expression is increased in bone marrow endothelial cells after G-CSF administration. The 
net effect is a shift in the balance of chemokine production to the endothelium, thereby 
promoting neutrophil release from the bone marrow.  
In summary, this study provides evidence that ELR
+
 CXCR2 ligands are a second 
chemokine family that, together with CXCL12, controls neutrophil trafficking from the 
bone marrow.  Although most cases of WS are associated with autosomal dominant, 
gain-of-function mutations in CXCR4, several pedigrees have been reported that lack the 
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characteristic mutations (9, 11, 14).  Balabanian and colleagues reported a WS pedigree 
with decreased expression of GPCR kinase-3 (GRK3), a protein that negatively regulates 
CXCR4 signaling (59).  Recently, homozygous, loss-of-function mutations in CXCR2 
have been identified in a pedigree with isolated myelokathexis (George A. Diaz, personal 
communication).  Our data provide experimental evidence that loss-of-function mutations 
in CXCR2 are sufficient to induce a myelokathexis phenotype in mice.  Of potential 
clinical relevance for the treatment of patients with myelokathexis and CXCR2 mutations, 
our studies of CXCR2
-/-
 neutrophils suggest that mobilization responses to AMD3100 or 
G-CSF may be impaired.  
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3.9 Figures and figure legends 
 
 
 
Figure 3-1.  Legend on next page. 
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Figure 3-1.  CXCR2-/- neutrophils are selectively retained in the bone marrow of 
mixed chimeras.  (A) Generation of mixed chimeras: bone marrow cells from wild-type 
(WT) Ly5.1+ and CXCR2-/- Ly5.2+ mice (1 x 106 cells from each) were mixed in a 1:1 ratio 
and transplanted into lethally irradiated congenic wild-type (Ly5.1+) recipients. Mice were 
analyzed 6-8 weeks after transplantation.  (B) Representative dot plots showing the 
contribution of wild-type (Ly5.1+) and CXCR2-/-  (Ly5.1-) cells to neutrophils (Gr-lhi) in the 
blood and bone marrow.  (C) Quantitation of mature neutrophils (Gr-1hiSSChi) in the 
blood, bone marrow, and spleen.  (D) The neutrophil distribution index (NDI) was 
calculated to estimate the percentage of total body neutrophils in the blood using the 
following formula: NDI = blood neutrophils/(blood + bone marrow + spleen neutrophils).  
(E) Shown is the number of B lymphocytes (B220+) or T lymphocytes (CD3+) in the blood 
(left panel) and B lymphocytes in the bone marrow (right panel).  T lymphocyte 
chimerism was assessed 6 months after transplantation (n = 3).  (F) Shown is the 
number of wild-type or CXCR2-/- CFU-C or CFU-G in the bone marrow (n = 3). Unless 
otherwise noted, data represent the mean ± SEM of n = 27 (blood) or n = 6 (bone 
marrow and spleen) mice from at least 3 independent transplantations. 
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Figure 3-2.  CXCR2 deficiency produces a myelokathexis-like phenotype.  
(A) Representative dot plots of mixed chimera bone marrow showing the percentage of 
Gr-1hi SSChi cells within the total Gr-1+ myeloid cell population for wild-type (WT, left 
panel) or CXCR2-/- cells (right panel). (B) Shown is the percentage of Gr-1hi SSChi cells 
within the total Gr-1+ myeloid cell population for n = 7 chimeric mice from 2 independent 
transplants.  (C) Representative photomicrographs of sorted wild-type (left panel) or 
CXCR2-/- Gr-1+ cells (right panel).  Scale bar = 20 µm.  (D) Manual leukocyte differentials 
of sorted cells from n = 5 mice from 2 transplants. The data represent the mean ± SEM.  
***P < 0.001, 2-way ANOVA. 
128 
 
 
 
Figure 3-3.  Mobilization of CXCR2-/- neutrophils by G-CSF is impaired.  (A) Mixed 
chimeras (n = 5) were given a single injection of G-CSF (125 µg/kg) and the absolute 
neutrophil count for each genotype was determined 1.5 hours after injection.  (B) G-CSF 
(125 µg/kg per day, twice daily) was administered to a separate cohort of n = 5 chimeric 
mice for 5 days, and blood neutrophils were quantified.  (C) The number of wild-type or 
CXCR2-/- Gr-1+SSChi cells in the bone marrow (left panel) or spleen (right panel) after 5 
days of G-CSF administration.  (D) The calculated neutrophil distribution index after 5 
days of G-CSF.  The data represent the mean ± SEM.  †P < 0.05, ‡P < 0.01 compared 
with time 0; **P < 0.01, ***P < 0.001 compared with CXCR2-/- cells at the same time 
point, 2-way ANOVA.
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Figure 3-4.   CXCR2 and CXCR4 signals interact antagonistically to regulate 
neutrophil release.  (A) Representative dot plot (left panel) or the MFI of n = 5 mixed 
chimeras (right panel) showing cell-surface CXCR4 expression of wild-type (Ly5.1+) and 
CXCR2-/- (Ly5.1-) bone marrow cells gated on the Gr-1+SSChi population. (B) CXCR2-/- 
mixed chimeras (n = 5) were given a single subcutaneous injection of AMD3100 (5 
mg/kg) and neutrophils quantified at the indicated time.  (C,D) Number of neutrophils in 
the bone marrow and spleen and neutrophil distribution index at 1 hour after AMD3100 
administration (n = 3).  (E,F) LysMCre/+ CXCR4flox/- (MKO, n = 10) and LysMCre/+ 
CXCR4flox/- CXCR2-/- double knockout (DKO, n = 4) mixed chimeras were established as 
described in Figure 1.  Blood, bone marrow and spleen neutrophils and the neutrophil 
distribution index were quantified 7 weeks after transplantation.  (G) CXCR4-MKO mixed 
chimeras (n = 3) were given a subcutaneous injection of GROβ (100µg/kg), and the 
number of wild-type and CXCR4-/- neutrophils in the blood measured after one hour.  
Data represent the mean ± SEM.  ***P < 0.001, 1-way ANOVA (panels e and f).  ‡P < 
0.01 compared with time 0; **P < 0.01, ***P < 0.001 compared with wild-type cells at the 
same time point, 2-way ANOVA (panels b and g).  
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Figure 3-5.  Legend on next page. 
131 
Figure 3-5.  CXCR2 ligands are produced by bone marrow stromal cells and 
regulated by G-CSF.  (A) Bone marrow endothelial cells (7AAD- CD45low Ter119low 
CD31+) or osteoblasts (7AAD- CD45low Ter119low GFP+) were isolated by cell sorting from 
Col2.3:GFP transgenic mice.  Shown are representative dot plots depicting the sorting 
strategy.  (B) Shown is the normalized gene chip signal at baseline for all chemokines 
with an average signal intensity of greater than 400 in at least one of the cell types.  
Where more than one probe set existed, the highest signal was selected.  Pf4 encodes 
for CXCL4, Ppbp encodes for CXCL7, and Mif is a non-chemokine ligand for CXCR2 
and CXCR4 (60).  (C) Expression of CXCR2 and CXCR4 ligands in endothelial cells 
from wild-type mice at baseline or after G-CSF administration.  (D)  CXCL2 protein in 
bone marrow supernatant at baseline or after G-CSF was measured by ELISA (n = 4 
mice per group).  The dashed line represents the limit of detection for the assay.  Data 
represent the mean ± SEM.  *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA. 
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Figure 3-6.  Tug-of-war model of neutrophil trafficking from the bone marrow.  See 
text for details.  
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Summary and future directions 
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4.1 Summary 
A broad array of diseases are associated with dysregulation of the inflammatory response, 
and neutrophils are a key initiating component of this response.  Therefore, it is vital that 
organisms maintain precise control of circulating neutrophil numbers to ensure adequate 
protection against pathogens while minimizing damage to host tissue.  Blood neutrophil 
homeostasis is determined by the integrated control of neutrophil precursor proliferation 
and differentiation in the bone marrow, release of mature neutrophils from the bone 
marrow, and clearance of aged, senescent neutrophils from the circulation by 
margination, transmigration across the endothelium, apoptosis, and phagocytosis.  
Equally important is the ability to rapidly alter homeostatic levels of these processes in 
order to mount an effective neutrophil response to infection or other stresses. 
 This thesis has increased our understanding of the role of the neutrophil 
chemokine receptors CXCR2 and CXCR4 in the regulation of neutrophil homeostasis.  
To study chemokine signaling in neutrophils, we used cells genetically deficient for 
CXCR2, CXCR4, or both receptors.  Our goals were:  1) to characterize the role of 
CXCR2 and CXCR4 signaling in basal and stress granulopoiesis. 2) to characterize the 
role of CXCR2 and CXCR4 signaling in neutrophil clearance.  3)  to define the nature of 
the interaction (if any) between CXCR2 and CXCR4 in the regulation of neutrophil 
homeostasis. 4)  to identify the chemokines produced in the bone marrow, their cellular 
source, and how they are regulated. 
Our results show that CXCR4 is a dominant, common pathway regulating 
neutrophil release from the bone marrow under basal and stress conditions, but it is not 
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essential for neutrophil clearance from the circulation (Chapter 2).  CXCR2 opposes 
CXCR4 in the regulation of neutrophil release from the bone marrow.  It is required for 
egress into the tissues and proper sensing of neutrophils by tissue phagocytes, but cell-
intrinsic CXCR2 signals play a minor role, if any, in the regulation of neutrophil 
production (Chapter 3).  CXCR2 and CXCR4 ligands are highly produced by bone 
marrow endothelial cells and osteoblasts.  Their expression pattern and regulation by G-
CSF suggests a tug-of-war model where the balance of pro-retention chemokines 
produced by osteoblasts and mobilizing chemokines produced by the endothelium 
regulates the level of neutrophil release from the bone marrow (Chapter 3).  Our data in 
genetic knockout mice supports a causative role for CXCR2 and CXCR4 mutations in the 
pathogenesis of the human disease WHIM syndrome. 
 
4.1.1 CXCR4 myeloid conditional knockout mice 
A significant amount of genetic and pharmacologic data in humans and mice suggested 
that CXCR4 may be a key retention signal for neutrophils in the bone marrow.  Even 
more intriguing, a series of studies by Dr. Sara Rankin and colleagues had suggested that 
modulation of CXCR2 and CXCR4 signaling may regulate the return of senescent 
neutrophils to the bone marrow where they are ultimately cleared by apoptosis and 
phagocytosis (1, 2).  However, the interpretation and analysis of all the existing data was 
complicated by limited samples from patients with WHIM syndrome, perinatal lethality 
in CXCR4-deficient mice, the potential confounding effects of CXCR4 signaling in 
precursor cells or other lineages in the bone marrow, ex vivo manipulation and aging of 
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neutrophils, and the inherent limitations, such as off-target effects or incomplete 
inhibition, of drugs or antibodies.  In Chapter 2, we utilized mice with a conditional 
deletion of CXCR4 restricted to cells of the myeloid lineage to assess the function of 
CXCR4 in neutrophils and overcome many of these limitations. 
 Using these mice, we confirmed that CXCR4 acts as a key retention signal that 
negatively regulates neutrophil trafficking from the bone marrow.  We also show that 
although CXCR4 mediates homing of circulating neutrophils to the bone marrow, this 
site is not essential for neutrophil clearance, suggesting that other organs (spleen, liver, 
lung) can compensate for impaired bone marrow clearance without a requirement for 
CXCR4.  
The role of CXCR4 in neutrophil mobilization in response to infection or stress is 
not clear.  In general, there is evidence both for and against the presence of distinct 
pathways in basal versus stress granulopoiesis, between various sites of infection, and 
between different bacterial and fungal pathogens.  To answer the question of whether 
CXCR4 is a final common pathway that mediates both basal and stress granulopoiesis, 
the neutrophil response of the myeloid conditional CXCR4 knockout mice to several 
important classes of inflammatory mediators (cytokines, G-CSF; chemokines, CXCL2) 
and a murine model of lethal bacterial infection (Listeria monocytogenes) was measured.  
The results suggested that disruption of CXCR4 signaling is the mechanism of neutrophil 
mobilization in response to these diverse classes of stimuli.  Of note, consistent with the 
normal homeostatic clearance of CXCR4-deficient neutrophils, CXCR4 was not required 
for neutrophil emigration into the peritoneum in response to L monocytogenes infection. 
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4.1.2 CXCR2 chemokines mediate neutrophil release 
Having shown that CXCR4 seems to be a master retention signal for neutrophils in the 
bone marrow, we hypothesized that other signals must exist that oppose CXCR4 and 
direct the key steps of neutrophil mobilization:  disruption of adhesive interactions with 
the bone marrow extracellular matrix, chemotaxis toward the vasculature, and 
transmigration across the endothelial barrier into the circulation.  The alternative 
hypothesis is that constitutive mobilization is the default program that occurs by mass 
action of neutrophil production in the bone marrow and random chemokinesis.  Under 
this model, CXCR4 evolved to limit excessive inflammation and tissue damage from 
circulating neutrophils.  Work presented in Chapter 3 suggests that CXCR2 may be one 
such opposing signal. 
 Given the essential role of CXCL12, it seemed logical that other chemokines 
might play a role in regulating neutrophil mobilization.  CXCR2 chemokines were 
attractive candidates because of the high expression of CXCR2 on mature neutrophils and 
the diverse neutrophil functions mediated by CXCR2 signals.  Furthermore, CXCR2 
ligands were already known to be rapid and potent mobilizing agents.  However, the 
mechanism of their action (activation versus chemotaxis, cell-extrinsic versus cell-
intrinsic) and whether they had a more general, endogenous role in basal neutrophil 
release or neutrophil mobilization by other classes of agents was unclear.  At about the 
same time, mutations in CXCR2 associated with myelokathexis were reported.  Together, 
this data supported the idea that CXCR2 positively regulated neutrophil release from the 
bone marrow. 
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 Stromal cells in the bone marrow are likely to produce a number of molecules, in 
addition to CXCL12, that are important in regulating neutrophil trafficking.  In particular, 
endothelial cells are highly transcriptionally active and are known to perform a variety of 
intercellular signaling functions, including mediation of neutrophil extravasation, in the 
peripheral circulation.  Their function as a physical barrier to the circulatiion predicts that 
endothelial cells play a key role in regulating neutrophil release.  To address these 
possibilities, we performed a survey of gene expression in osteoblasts and endothelial 
cells and measured endothelial cell changes in response to G-CSF using gene expression 
arrays as described in Chapter 3.  Although additional candidate molecules need to be 
assessed, an unbiased analysis of gene expression changes using SAM and a curated 
assessment of all chemokines provided further evidence that the CXCR2 was a key 
positive regulator of neutrophil release.  The CXCR2 chemokines CXCL1, CXCL2, and 
CXCL7 were highly expressed, with higher expression in endothelial cells and increased 
CXCL2 expression in endothelial cells after G-CSF. 
 CXCR2-deficient neutrophils in mixed bone marrow chimeras were used to 
confirm this potential role for CXCR2 in neutrophil release.  As mentioned above, the 
cause of the myeloid expansion in CXCR2-deficient mice is not clear (3-5).  Although 
further experiments need to be done to confirm these conclusions, our data suggest that 
the neutrophilia in these mice is caused by an interruption of the neutrostat feedback loop 
involving suppression of IL-23, IL-17, and G-CSF production by phagocytosis of 
neutrophils in peripheral tissues.  Our results argue against excessive cell-intrinsic 
proliferation or passive accumulation of CXCR2-deficient neutrophils as an explanation 
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for the neutrophilia.  Alternatively, CXCR2 may interact with other, as yet 
uncharacterized components of this feedback loop.  Specifically, CXCR2 may be 
important for interactions with endogenous bacteria or clearance of subclinical infections 
that affect cytokine production and neutrophil homeostasis.  The environmental 
conditions of mice or humans with CXCR2 mutations (germ-free, specific pathogen-free, 
or the normal range of pathogens in the everyday world), must be considered when 
making generalizations from observed alterations in neutrophil counts.  Finally, CXCR2 
signaling in non-hematopoietic cells, particularly endothelial cells, may play a role in 
regulating neutrophil and lymphocyte homeostasis. 
 Our results suggest that CXCR2 is a second chemokine pathway that positively 
regulates neutrophil release.  We show that CXCR2-deficient neutrophils reproduce a 
myelokathexis phenotype consistent with the recently described human mutations.  
CXCR2 appears to play a role in the stress granulopoiesis response to G-CSF.  The data 
indicate that CXCR2 is more important in regulating the immediate (minutes to hours) 
release of neutrophils after G-CSF treatment.  CXCR2 has a more minor role in 
neutrophil mobilization after prolonged (days) of G-CSF, probably because of the 
additional effects of G-CSF-induced proliferation, transcription, and microenvironmental 
changes in the bone marrow. 
 CXCR2 and CXCR4 interact antagonistically to regulate neutrophil release from 
the bone marrow.  However, CXCR4 appears to play a dominant role, as neutrophils 
lacking both CXCR2 and CXCR4 still display constitutive mobilization.  The importance 
of CXCR2 signaling in neutrophil trafficking likely decreases with increased magnitude 
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or duration of CXCR4 inhibition.  Our experiments did not definitively answer whether 
CXCR2 antagonizes CXCR4 signaling through heterologous interactions.  On one hand, 
we did not observe any alteration in CXCR4 expression in the absence of CXCR2, 
arguing against heterologous regulation of receptor expression.  In contrast, CXCR2 had 
no effect on neutrophil counts in the complete, genetic absence of CXCR4, consistent 
with a mechanism for CXCR2 that acts through CXCR4.  One such mechanism is 
heterologous desensitization or internalization. 
Chemokine receptors, like many GPCRs, can undergo heterologous regulation of 
their signals at many different levels.  They can homo- or hetero-dimerize or even form 
higher oligomers.  Desensitization or internalization signals generated by one receptor 
can cross-desensitize or –internalize other related receptors.  The regulatory mechanisms 
in play are highly dependent on the cell type, specific receptor, and environmental 
mileau.  Therefore, additional experiments will be required to determine what, if any, 
interactions there are between CXCR2 and CXCR4 that are important for the phenotype 
observed in CXCR2-deficient neutrophils.  Of note, heterologous desensitization between 
CXCR4 and CXCR2 has been demonstrated in ex vivo cultured monocytes (6) and 
neutrophils (7).  Wild-type or WHIM-mutant CXCR4 can form dimers at the cell surface 
in cell lines (8).  Recently, our collaborator Dr. George Diaz has demonstrated physical 
interaction between CXCR4 and CXCR2 (unpublished data) in neutrophils. 
Our results show that the integration of CXCR2 and CXCR4 signals by 
neutrophils in the bone marrow is a key pathway regulating their release.  Our data and 
others suggest that this signaling axis may be important in immunodeficiency, infectious 
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and inflammatory disease.  The CXCR2- and CXCR4-deficient mouse models described 
in this thesis could be tested in additional models of infection to further investigate this 
possibility.  Drugs that activate or inhibit these receptors should be tested in models of 
acute (sepsis, ARDS) or chronic (rheumatoid arthritis) inflammatory disease.  Indeed, our 
data suggest that prolonged G-CSF treatment but not AMD3100 treatment would be 
effective in treating patients with myelokathexis and CXCR2 mutations.  The efficacy of 
chronic AMD3100 treatment in CXCR2-deficient neutrophils needs to be tested.  
Conversely, either AMD3100 or G-CSF (the currently used therapy) would be effective 
in other genotypes of WHIM syndrome. 
 
4.2 Future directions 
4.2.1 Expression of chemokines and other molecules by bone marrow stromal cells 
The production of CXCL1 and CXCL2 in bone marrow endothelial cells and osteoblasts 
needs to be confirmed.  Several methods are currently being employed to accomplish this 
goal.  Bone marrow stromal cells will be sorted as described in Chapter 3 and expression 
of CXCL1, CXCL2, CXCL7, and CXCL12 will be measured by qRT-PCR.  We are also 
currently working to develop a flow cytometry assay to measure CXCL1 and CXCL2 in 
endothelial cells.  Finally, as was done with CXCL12, Adam Greenbaum in our 
laboratory is working to stain bone marrow histologic sections for CXCL1 or CXCL2 
and co-localize these proteins with endothelial cell or osteoblast-specific markers.  We 
will also look at these histologic sections to assess any changes in the overall architecture 
of the bone marrow after G-CSF administration or inhibition of CXCR4 by AMD3100.  
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Is CXCR4 inhibition associated with increased amounts of neutrophils near the 
vasculature or absence of neutrophils near the endosteum?  When these assays are 
developed, we will also measure chemokine expression after shorter courses of G-CSF to 
try to explain the differences observed in CXCR2-deficient neutrophils after short- versus 
long-term G-CSF.  Alternatively, a GFP reporter construct could be knocked in to the 
CXCL2 locus and GFP expression measured by flow cytometry or histology to confirm 
the cell types that express CXCL2 and its regulation by G-CSF. 
 Although the chemokine expression data supports the tug-of-war model for 
neutrophil release, the requirement for these chemokines has not been demonstrated.  To 
determine the biological significance of chemokine expression in specific stromal cell 
subsets, Adam Greenbaum is developing a transgenic mouse system with a floxed 
CXCL12 allele that will allow for osteoblast- (using OSTERIX-CRE mice) or endothelia- 
(using TIE2-CRE mice) specific deletion of CXCL12.  Our model predicts increased 
neutrophil release with osteoblast deletion and normal or decreased release with 
endothelial deletion.  If this strategy proves successful, we would pursue a conditional 
deletion model of CXCL2 and possibly even CXCL1.  An alternative but less desirable 
strategy would be to overexpress these chemokines using transgenes specific for 
osteoblasts or endothelial cells.  These types of models are subject to dysregulated 
expression and leaky expression outside of the target cell population.  Furthermore, some 
of these approaches have already been reported in the literature (9).  Actually, this report 
supports the tug-of-war model since vascular CXCL12 expression in the absence of 
osteoblast CXCL12 resulted in decreased myeloid cells in the bone marrow.  However, it 
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is clear from the CXCR4 myeloid conditional knockout mice and our CXCL12 
expression data that under normal conditions CXCL12 derived from osteoblasts acts as a 
retention signal that far outweighs any pro-mobilizing effect of CXCL12 produced by 
bone marrow endothelial cells. 
 We will also perform further analysis on our existing gene chip data and 
expression arrays performed in Dr. Tim Ley’s laboratory on neutrophils differentiated in 
vitro (10) to search for additional molecules that may regulate basal or G-CSF induced 
neutrophil release from the bone marrow. 
 
4.2.2 Mouse models of WHIM syndrome 
Retroviral overexpression of WHIM-mutant CXCR4 has been reported (11) but is subject 
to confounding effects of dysregulated expression, insertional mutagenesis, and the 
xenotransplant setting.  A long standing but yet to be accomplished goal of this work has 
been to develop a “knock in” transgenic mouse model of WHIM syndrome by expressing 
the CXCR4 R334X mutant under the control of the endogenous CXCR4 promoter.  Our 
preliminary data indicate that this locus is extremely resistant to homologous 
recombination, as only one out of more than 1,000 neomycin-resistant ES clones 
displayed targeted recombination.  Although human WHIM syndrome is not a highly 
lethal disease, another possibility is that in the mouse ES cells this mutation is toxic.  
CXCR4 is expressed throughout development, including in ES cells, and the mutation 
acts in a dominant fashion.  One report demonstrated that merely slightly altered levels of 
CXCR4 signaling could affect developmental processes (12).  In mouse embryos, 
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expression of mutant CXCR4 impairs viability.  In embryos generated from chimeric 
blastocysts derived from the one correctly targeted ES clone, a high level of chimerism as 
assessed by coat color resulted in lethality.  Using an albino B6 recipient blastocyst, 3/25 
mice with black eyes were dead at birth, while the surviving 22 mice were all white.  In 
chimeric pups with chimerism assessed by expression of a lacZ transgene in red blood 
cells, 2/10 mice displayed some lacZ activity, but this level of chimerism resulted in 
infertility and resultant inability to obtain germline transmission of the mutation. 
Current efforts by Ryan Day in the lab are focused on generating inducible 
heterozygous expression of the mutant CXCR4 so that prior to Cre induction mice will 
merely be haploinsufficient for CXCR4.  As described above, CXCR4
+/-
 mice are 
essentially normal.  Such a system for other genes has been reported in the literature, and 
we are using a construct similar to the one described (13).  If these mice can be 
generated, they would confirm that CXCR4 mutations are responsible for the 
pathogenesis of WHIM syndrome.  The mechanisms of viral infection, brain tumors, and 
altered B lymphocyte function in addition to the altered neutrophil trafficking could be 
dissected.  The mice would provide a tool to profile the intracellular signaling molecules 
that mediate neutrophil release.  For example, it is unclear whether GRK6, GRK3 or both 
are the key regulators of CXCR4 desensitization (14, 15).  
 
4.2.3 Importance of stromal CXCR2 expression 
In the process of generating chimeras with CXCR2-deficient neutrophils, we predicted 
that wild-type mice reconstituted with CXCR2
-/-
 hematopoiesis would recapitulate the 
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neutrophilic phenotype of CXCR2
-/-
 mice.  However, some chimeras were generated with 
only CXCR2
-/-
 cells, and, to our surprise, these mice were neutropenic with no evidence 
for myeloid expansion.  This suggests two possibilities:  1)  Given the data in germ-free 
CXCR2
-/-
 - mice, there may be a critical period during which subclinical infection or 
endogenous bacteria can become dysregulated and induce excessive cytokine production.  
This may occur during the neonatal period.  Alternatively, the conditioning regimen for 
bone marrow transplant may interrupt this process.  2)  CXCR2 expression on non-
hematopoietic, radio-resistant cells (such as endothelial cells) may prevent neutrophilia.  
To address the role of non-hematopoietic CXCR2 signaling in neutrophil homeostasis, 
we are generating chimeras derived from CXCR2-/-  recipient mice reconstituted with 
wild-type cells, or CXCR2-/- cells transplanted back into CXCR2-/- recipients as a 
control.  These experiments may demonstrate a novel role for endothelial CXCR2 in 
neutrophil homeostasis. 
 
4.2.4 Signaling studies 
As discussed above, our experiments did not completely determine the role of 
heterologous interactions between CXCR2 and CXCR4 in the regulation of neutrophil 
trafficking.  We will use CXCR2- or CXCR4- deficient neutrophils in chemotaxis and 
calcium flux assays to measure any alterations in signaling in the absence of one of these 
two receptors.  If heterologous interactions are responsible for myelokathexis in CXCR2
-/-
  
mice or humans, we would predict that CXCR4 signaling would be increased in the 
absence of CXCR2.  We will attempt to measure signaling in conditions that mimic either 
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basal or stress conditions.  According to a recent report, β-arrestin transmits CXCR4 
signals through ERK phosphorylation (16), so we will also attempt to measure CXCR4 
signaling in freshly isolated neutrophils using a phosphoflow assay previously utilized in 
LKS cells by our lab (17). 
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